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Onwards 
Laura Hinz (Meds 2011) 
W hen faced with the word " techno logy," images of robots, supercomputers, and rna sive e lectri ca l circuit spring to mind . However, the concept of technology stems fro m 
Greek th inkers, long before the introducti on of any of tho e devices .1 
Technology encompasses more than gadgets and gizmos, it invo lves 
any nove l way of thinking, creating, or orga nizing that a ims to solve 
a problem. Thus Hea lth Technology was an ideal theme for an issue 
of the UWOMJ , whose mandate has always been to in pire and 
ce lebrate new, innovati ve approaches to medic ine. 
In thi issue Dhaliwa l and Ba llantyne describe a technique that 
use the bodies own ce ll s to heal art icul ar cartil age injuries. Thi s 
artic le illustrates the perfect union between health and technology by 
suggesting the idea that if manipulated correctl y, the body itse lf can 
be a so urce of hea ling. However, the technophiles will find the more 
common conception of technology in an e loquent arti c le by 
MacPherson and Rav ichand iran, describing adva nces in the fi e ld of 
microfluidics engineering. 
I approached thi s issue with a certa in degree of trepidati on, as 
c ircuits and computer remain reso lute ly beyond my grasp. Those 
w ith s imilar limitati ons will find hope in Gotthe il and Kudl ow 's 
arti cle, whi ch describes an adaptat ion of a common technology 
(namely text messaging) to serv ice a hea lth ni che. Not onl y is thi s a 
resource-effi c ient approach to techno logy, but it puts technologica l 
deve lopment within the grasp of each indi vidual. You do not need to 
be an eng ineer in order to develop technology; you simply need to be 
inquisiti ve, observant, and creati ve. 
Whil e the ultimate goa l of technology is to so lve problems, it 
can a lso create new ones in its wake. For in tance, the Medi cine and 
the Law editors ex plore the ethica l implications of direct-to-
consumer genetic testing. With the deve lopment of new technology, 
we must consider how it will be utilized, who it wil l affect, and what 
furth er changes it w ill bring. 
The introduction of technology can a lso he lp to legi timi ze an 
a ilment by providing a solution. There are several "culture bound 
syndromes," those that ex ist among certain groups onl y2 Severa l 
years ago, the medica l schoo l curri culum would not have inc luded 
erectile dysfun ction . With very few treatments availabl e, the sti gma 
that shrouded this di sorder prevented many men from admitting to 
symptoms. With new techniques such as those described by Kudlow 
and Radomski , the prospect of cure ha led to erectil e dys fun ction 's 
recognition as a legitimate diagnosis. 
The phrase " Hea lth Technology" implies a separate part o f the 
whole, a branch o f study unto its own. However, innovations in a 
variety of fi e lds have had an impact on medic ine. In hi s book "The 
Bra in that Changes Itself," Dr. Doidge suggests that the concept of 
bra in plasticity was initi ally li mited by the prevailing mechani sti c 
view of the brain .3 Great advances were be ing made in engineering, 
which led sc ienti sts to liken the brain to a machine. Machines do not 
grow and change, thus the idea that the bra in could adapt after illness 
or injury was disregarded. With the di scovery of e lectri city, a new 
conceptualization of the brain unfolded with the suggesti on that 
nerves re li ed on changes in current. It is thus reasonable, and 
perhaps vita l, to look beyond medi c ine for medica l techno logies. 
We have een countless exam ple of the impa t of techno logy 
on medicine- e lectroni c hea lth records, genomic seq uencing, robotic 
surgery. Perhaps less obvious is the impact of technology on each 
indivi dua l's habits and ways of thin king. Thi s journa l is in print 
fo rm, as many peop le object to reading off a screen. Why? There is 
nothing innate in our bra in that says that the printed word must be 
black on a white background, sized 8.5x 11 wi th page that can tu m . 
If you handed a book to someone accustomed to scro ll s, they may 
regard it with the same disda in as I currently reserve fo r e-readers. 
As technology evo lves, our determ ination of what is normal or 
comfortable will change. If our editors had been asked to w ie ld an 
o ld-fashi oned pen fo r thi s issue, the arti cles may have been much 
briefer as they lamented the loss of the qui cker and more ergonomic 
word processer. 
As thi s is my last contribution to the UWOMJ , I would like to 
thank all of the writers, facul ty, adverti sers, and readers who make 
thi great pub li cation possible. This issue ex plores fo rays into the 
unknown, attempts to expand our knowledge and improve our abili ty 
to hea l. To the Class of 20 II , thi s i exactly what we will be 
attempting to do as we head off on our vari ous res idencies. I urge 
you to take the lessons of fo ur years of c lini c, c lass, and camaraderie 
and temper it w ith the sage advice to ' don' t stop be li ev ing.' 4 
REFERENCES 
I. Online Etymology Dictionary. http://www.etymonl ine.com/ index .php? 
term=techno logy. Accessed 09/02/20 II . 
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The use of nanotechnology in cancer 
management 
Yu ding Wang (Meds 2013)*, Chanseok Rhee (Meds 2013)*, Nianxin Jiang (Meds 2013)* 
Suga nt h Suppiah (Meds 2013)*, Zoya Bahreini (Meds 2013)* 
*Following authors contributed equally to this paper. 
Faculty Reviewer: Dr. C. Hamm (Department of Oncology, Windsor Regional Cancer Centre) 
D rug deli very y terns have prov ided the phannaceuti ca l industry a means of improvi ng the therapeuti c properties of pre-ex i ting drugs. These systems, such as lipid- or polymer-
based nanoparti cles, alter the pharmacokineti cs and biodi stributi on of 
the drug that is being carried 2 A nanoparti c le is forma ll y defin ed as 
an eng ineered parti c le in nanometer ize. The inherent properti es of 
the nanopartic le make it an idea l vector to di stribute drugs. The 
submi cron size, with di ameters less than 200 nm, of the nanopartic le 
increases its intrace llular uptake, abili ty to penetrate through 
submucosa l layers and cross the blood bra in barrier. 2·3 Both synthetic 
and organic po lymers have been utilized to create biodegradable 
nanopartic les, like the po lylactides that undergo hydro lysis upon 
implanta tion and broken down to lactic acid . The drugs are re leased 
via diffusion across the po lym er matri x and through biodegradation 
of the polymer itse l f.3 anoparti c les conjugated with ti ssue-speci ti c 
li gand also all ow the deli very of the drug to be more targeted, and 
reduce the amount of side e ffects.3.4 As a result, nanopartic les have 
the potential to increase the potency and e ffi cacy of the drugs that are 
a lready used in practi ce. 
Nanoparticle could vastl y improve the tools we have to fi ght 
cancer through a two- fold approach: ( I) earl y detection o f cancer 
and (2) cancer therapeuti cs. The nanoparti cles target the site o f the 
cancer for both diagno ti c and therapeutic purpo es. The potenti al o f 
nanoparti cles in the fi eld o f oncology i ho ld many promises. 
NANOTECHNOLOGY FOR CANCER DIAGNOSIS 
Various nanoparti cles such as ironox ide crystals, and QD emi -
conductor non-crysta ls, have shown great potenti a l for detecting 
di sease markers, pre-cancerou s ce ll s, fragments o f viruses, speci tic 
prote ins, antibodies and other di sease indicators. 5 
In the fi eld o f onco logy, nanoparti c les ca n ass i t to non-
invasively detect tumors at an ea rly stage, perhaps months or even 
years earlier than the conventi ona l di agnostic too ls would make the 
same diagnos is, and thus result in max imum therapeuti c benefit and 
improve the progno is o f the patients. For instance, in brea t cancer, 
nanomedi c ine can potentia ll y use molecular imaging to accurate ly 
di agnose breast ca ncer when the tumor ma has onl y I 00- 1 ,000 
ce ll s , as o pposed to th e curre nt im ag in g techniques like 
mammograph y, whi ch require the detecti on o f more than one mi ll ion 
tumor ce ll s for accurate c lini ca l diagnos is.6 
QDs are emi conductor nanocry tals made up o f I 00- 100,000 
atoms7 Q D conta in e lectrons, which after excitati on, can re lax to 
their ground state and release photon in the proce s, lead ing to a 
vis ibl e flu ore cence. The flu ore cent signa ls of Q Ds are I 0-100 tim e 
bri ghter compared to organi c dyes and the ir emiss ion properti e 
make it poss ibl e to overcome ti sue auto flu orescence 8 ·9 Also, 
spec ia ll y-eng ineered Q D coated with stea lth po lymer can resi t 
photobleaching and ce llular degradati on better th an conventi onal 
fluo rophores (molecules capable of flu orescence), a llowing studies to 
be carried out over time.10 Due to a ll the e unique characteri stics, 
QDs can be conjugated to anti bodies that have affi ni ty fo r tumor-
spec ific an tigens, and they wi ll preferenti ally loca li ze to the tumor 
cell s. The ide ntificat ion of the changes in ce llular surface protein 
concentration can be an earl y ind ication of cancer. 10 Other studies 
have show n that by injecting Q D-labe lled melanoma ce ll into mice, 
one can vi ua lize in vivo the migrati on of tumor ce ll s to the lungs on 
imaging.9 This abi lity to track tumor mi cro-meta tas i can lead to 
greater under tand ing of the behavior of metastati c cancer and 
d i covery of ne' treatment option . 
In practice, identification of the entine l lymph node (SLN) in 
breast cancer can be chall eng ing. Currently mapping is done by using 
blue dye and radi o i otope . Thi technique obscure the urg ical fie ld 
and can ca use rad iation to the pat ient and hea lth care providers. 
Superparamagnetic iron oxide nanoparticles a ll ows pre-operati ve 
MRJ v isualization and intra-operati ve magnetometer-aided detection 
of S L , remo ing the need fo r harm ful radi o iotope and obscuring 
dyes 8 
anoparti c le can a lso make important advancements in 
di agnos ing and imaging o f brain tumor , through both preoperative 
and intraoperati ve brain mass detecti on, a llowing for early detection 
of precancerou ce ll and improv ing the prognostic outcomes of 
cancer pati ent . Currentl y, the most wide ly u ed MRJ contra t agents 
are based on paramagnetic gado linium (Gd(lll) ). 11 While still 
a luable, the e ion are not without the ir problems. They tend to 
diffuse freely through a tumor and pre ferenti ally image area where 
there i prominent blood-brain barri er breakdown, providing limited 
enhancement of the infiltrating tumor marg in or areas of poorly 
va culari zed mi crometa tas is. Al so, the permeability of blood-tumor 
barri er is not homogenous, whi ch mea n that the ion cannot enter a ll 
area o f the tumor equa lly. Furthem1ore, thi s contrast materia l has 
di ffi cult y di c rimin atin g tum o r fro m CNS infl ammation or 
infecti ons. N anoparticles des igned to pre ferentia lly target tumor 
areas, uch a uch as Ferumox tran- 1 0, a dextrancoated iron oxide 
nan? parti cle, have been developed a new MRI contra t agents to 
avo1d many o f these problems and provide a wide r window of 
opportumty for tumor imaging and enhancement. II 
NANOTECHNOLOGY AS CANCER T H ERAPEUTIC 
Many conventiona l cancer therapeuti c agents work by induc ing 
~ellular tox1c1ty causmg cancer cell death . Although cancer cell a re 
mherentl y more susceptible to the e ffects of these agent , the e 
agent a lso a ffect normal cell . . Tl~i s p.uts a con traint on the do age 
and f~:que.ncy of treatment as 1t mev1tabl y ca.uses injllly to norma l 
cell s. . Th1s constraint o ften results 111 suboptimal treatment, which 
contnbu.tes to the persistence and recurrence of cancer after th e 
completiOn of chemotherapeuti c treatment. 13 Current advance 111 
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nanotechnology seek to resolve these therapeutic constrai nts by 
a llowing for specific targeting of cancer cell s helping to increase 
drug efficacy while limiting un wanted toxicity. 
Cancer specific nanoparticle directed drug de li very takes 
advantage of cancer physiology by both a pas ive and act ive drug 
de livery mechani sm. In the passive drug delivery mechani sm, 
nanoparticles are selective ly concentrated at the ite of the tumour by 
the enhanced permeability and retention effect (EPR). 14 The EPR 
work due to the inherent faulty physio logy of fast growing tumour. 
lt is known that tumours require angiogenesis for continued growth . 
However, the g rowth of these new blood vesse l is di sorganized and 
leaky due to enlarged junctions between endothelial cell as well as 
defi c iencies in the underlying basement membrane.15 Whi le normal 
endothelium junctions are typicall y 5 to I 0 nm in ize, 13 gaps 
between the leaky endothe lium of the tumour are signifi cantl y larger 
and range from I 00 to 750 nm.16 Concurrently, the di sorgani zed 
growth of the tumour a lso results in formation of a disorganized 
lymphatic network.14 The leaky va culature and the lack of a 
lymphatic network result in the accumulation of nanoparticles in the 
cancer interstitium, passivel y concentrating drug at the site of the 
tumour.14 Novel nanoparti cle chemotherapy, Doxil (a pegy lated 
liposomal doxorubicin nanoparticle), takes advantage of the EPR. In 
vitro experiments have shown Doxil to have a I 0-fo ld increase of 
doxorubicin concentration (the chemotherapeutic drug (or payload)) 
within the tumour compared with conventional doxorubicin 
administration. 17 A lthough clinical trials comparing Doxil and 
conventional doxorubic in administration have shown no stati tical 
improvement in survival (overall and disease free) , Doxil was 
neverthe less shown to significantly decrease the ri sk of cardiotoxic 
effects of doxorubicin use (a significant side-effect limiting dosage 
and usage) .17 It shou ld be noted that the pegylation procedure helps 
the nanoparticle escape from macrophage detection 18, whi le the 
lipo omal core structure helps protect the bound doxorubicin to 
achieve a significantly longer half-life than free doxirubincin a lso 
contributing to the increased concentration of drug seen at the si te of 
tumour.1 7, 18 
The active drug delivery mechanism works by targeting specific 
receptors preferentially expressed on the tumour cell. For example, 
folate receptors are preferentiall y expressed in some cancer 
phenotypes whi le showing limited expression in normal ti ssue .19 
Experimental findings in mouse model s comparing conventional 
paclitaxel (given as free drug) with a heparin-folate-taxol (heparin as 
carrier molecule and fo late as targeting molecule) showed the folate-
directed nanoparticles to have more potent activity against tumour 
growth. 12 Another example is the transferrin receptor. In vitro studies 
using MCF-7 (human breast cancer cell line) comparing transferrin-
conjugated paclitaxel-loaded nanoparticles treatment versus free 
paclitaxel showed the transferrin-conjuated paclitaxel treatment to 
have greater inhibitory effect on cell growth.20 
Although drugs can be delivered to the tumour, another 
significant impediment remains due to chemotherapeutic drug 
resi stance. The most studied cause of resistance is the membrane 
associated protein pump p-glycoprotein (p-gp)2 1 The p-gp is 
expressed in a number of cell types in the body and functions to 
effectively pump chemotherapeutic agents out of the cell , conferring 
resistance. Nanoparticle drug design could sidestep this impediment 
by a number of poss ible mechanisms. One such mechanism is to co-
administer a p-gp antagonist along with the therapeutic drug, thus 
inhibiting the p-gp function. 21 Clinical trial s eva luating various 
potential antagonistic agents have shown disappointing results thus 
far, though new compounds continue to be discovered with improved 
binding specificity to p-gp21 Another mechani sm cou ld rely on 
receptor mediated endocytosis and subsequent endosomes formation 
as means for gaining access to the cell cytoplasm, which could 
effectively mask the nanoparticle until a high concentration of 
therapeutic drug is released to reach therapeutic effect, essentially 
overwhe lming the p-gp.12 In vitro and in vivo mouse model have 
shown that drug resistance can be overcome through thi mechanism . 
21 
Nanoparti c le as a means for drug delivery offers many unique 
benefits in the treatment of cancer compared to other targeted drug 
therapies proposed such as ant ibody-d rug conjugates . Firstly, 
nanopa rticles cou ld carry a significantly larger drug payload per 
ligand-receptor binding event compared to antibody-drug conjugates 
as we ll a being more versatile in the type of drug its ab le to carry 
since drugs are stored w ithin the nanopartic le, with limited exposu re 
to environment, while the type and number of drugs conjugated to an 
antibody cou ld ignificantly affec t its kinetics and biodistrubution. 18 
Secondly, nanopart icles are large enough to target multipl e li gands 
allowing for multiva li ent bind ing and se lectivity enhancement. 
Therefore, nanoparti c les can use mu lti ple weak ligand interactions to 
greatl y increase the pool of cancer binding targets whereas si ngle 
li gand recogn ition offered by antibody- conjugates require strong 
affi nity to be effective.22 Thirdly, nanoparticle des ign could allow the 
rate of release to be tailored for the drug of action . For example, 
topoi somerase I inhibitors such as the camptothecin-based drugs are 
reversible inhibitors of the enzyme, and therefore, have better 
efficacy if exposure of drug is pro longed 23 Lastly, nanopartic ls co uld 
a llow for the co- localization of different type of agents to work 
synergisticall y within the target cell to increase drug efficacy.22 
CONCLUSION 
Nanoparticles hold new promise as means for earlier detection 
and better treatment of cancer. Imagine a future where nanoparticles 
can help detect cancer before it even has a chance to manifest, and 
se lective ly destroy cancer cells while leaving the normal cells 
unharmed . Cancer, in such a ci rcumstance, cou ld become a hi ghl y 
manageable condition. However, despite our current resea rch there is 
much we still do not understand. Nanoparticles offer a new avenue to 
tackle these cha llenges. More research is needed in thi s promising 
and dynamic fi eld of cancer therapeutics. 
REFERENCES 
1. Canadian Cancer Society Cancer Statistic 2009 ; Avai lab le from : hllp:/1 
www.cancer.ca/canada-wide/about% 20cancer/cancer%20stat is ti cs/-/ 
med i a/CCS/C anada%20w i de/F i les%2 0 List/Eng! ish%20ti les%20head i ng/ 
pd f0/o20not%20in%20pub l ications%20section/S tats%202009 E% 20 dn 
%20Cancer.ashx 
2. Allen TM , and Cull is PR. Drug delivery system : entering the mainstream. 
Science. 2004 Mar I 9;303(5665): I 8 I 8-22. 
3. Panyam J, and Labhasetwar Y. Biodegradable nanoparticles for drug and 
gene delivery to ce lls and tissue. Adv Drug Deliv Rev. 2003 Feb 24;55(3): 
329-47. 
4. Moses MA, Brem H, Langer R. Advancing the fie ld of drug delivery: 
taki ng aim at cancer. Cancer Cell. 2003 Nov;4(5):337-4 I. 
5. Rathy Ravindran. anotechnology In Cancer Diagnosis and Treatment: an 
Overview. Oral and Max illofacial Pathology Joumal. 20 II Jan-Jun;2( I): 
101-106. 
6. Tanaka T, Decuzzi P, Cristofani lli M, et a/. Nanotechnology for breast 
cancer therapy. Biomed Microdevices. 2009 Feb; I I (I ):49-63 . 
7. Mazumder, S, Dey, R, Mitra , MK, et a/. Review : Biofunctionalized 
Quantum Dots in Biology and Medicine. Journal ofNanomateria ls, 2009 . 
8. Gunasekera UA, PankJlUrst QA, Douek M. Imaging app lications of 
nanotechnology in cancer. Target On col. 2009 Sep;4(3): I 69-8 I. 
9. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor 
cell extravasation with quantum dot nanocrystals and fluorescence 
emission-scanning micro copy. at Med . 2004 Sep; I 0(9):993-8. 
10. Ro enblum LT, Kosaka N, Mit unaga M, eta/. In vivo molecular imaging 
using nanomaterials: general in vivo characteristics of nano-sized reagents 
and applications for cancer diagnosis . Mol Membr Bioi. 20 I 0 Oct;27(7): 
274-85. 
UWOMJ I 80:1 I Spring 2011 5 
11. Ori ve G. Ali 0 , Anitua E, et a/. Biomaterial-based technologies fo r brain 
anti-cancer therapeutics and imaging. Biochim Biophys Acta. 20 I 0 Aug; 
1806( I ):96- 1 07. 
12. Cho K, Wang X. ie S, Chen ZG. Shin DM . Therapeutic nanoparti cle fo r 
drug deli very in cancer. Clin Cancer Re . 2008 Mar I ; 14(5): 13 10-6. 
13. Haley B, Frenkel E. Nanoparti cles for drug de livery in cancer treatment. 
Urol Oncol. 2008 Jan-Feb;26( I ):57-64. 
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor 
va culature: the key role of tumor-se lective macromolecul ar drug 
targeting. Adv nzyme Regul. 200 I ;41 : 189-207. 
15. Baban DF, eymour LW. ontrol of tumour va cular permeability. Ad v 
Drug Deli v Rev. 1998 Oct 5;34( I ): I 09-11 9. 
16. Campbell RB. Tumor physiology and deli very of nanopharmaceutical . 
Anticancer gem Med Chern . 2006 ov;6(6) :503- 12. 
17. Markman M. Pegylated liposomal doxorubicin in the trea tment of cancers 
of the breast and o ary. Expert Opin Pham1acother. 2006 Aug;7( II ): 
1469-74. 
18. Davi ME, Chen ZG. hin DM . 
treatment modali ty for cancer. 
771 - 2. 
anoparti cle therapeuti cs: an emerging 
at Re Drug Discov. 2008 ep;7(9) : 
19. hen H. Ahn R. Van den Bossche J,et a/. Folate-mediated intrace llular 
drug deli very increases the anticancer e ffi cacy of nanopart ic ul ate 
formulation of ar enic triox ide. Mol Cancer Ther. 2009 Ju1 ;8(7): 1955-63. 
20. ahoo K, Labh aset\\ ar V.Enh anced antipro li fe rati e ac ti\ ity of 
transferrin-conj ugated paclitaxel-loaded nanoparticles is mediated via 
sustained intrace ll ular drug retent ion. Mol Pharm . 2005 Sep-Oct;2( 5 ): 
373-83. 
21 . Thoma H, oley HM . Overcoming multidrug resistance in cancer: an 
update on the clinical trategy of inhibiting p-glycoprotein . Cancer 
ontrol. 2003 Mar-A pr; I 0(2) : 159-65. 
For more mforma1on 
contact Suns tar 
at 1 800 265·8353 
V1s1t GUMbrand.com 
22. Ferrari M. Cancer nanotechnology: opportunities and challenges. at Rev 
Cancer. 2005 Mar;5(3): 16 1-71. 
23 . Pommier Y. Topoi omera e I inhibitors: molecu lar and cellular 
detenninants of acti vity. 2003 . Available from : http://discover.nci .nih .gov/ 
pommier/topo !.hun 
SUN STAR 
2011 Sumlar An!HIU\o lilt l \1001 
6 UWOMJ I 80 :1 I Spring 2011 
Near-infrared spectroscopy to assess penile 
blood flow: a possible novel technique for the 
diagnosis of vasculogenic erectile dysfunction 
Paul A. Kudlow (Meds 2013), Sidney B. Radomski, MD, FRCSC 
Faculty Reviewer: Dr. Gerald Brock, MD, FRCSC (Division of Urology, Department of Urology) 
E rectile dysfunction (ED) i defi ned as the consistent inabili ty to achieve and maintain an erecti on uffic ient to pennit sati sfactory sexual perfo rmance or intercourse 1• The vast 
majori ty of cases of ED are primaril y of organi c and vascular 
etiology, although psychological factors also play a role in many 
cases 1• Affecting an e timated 2 milli on Canadi ans and becoming 
increas ingly common with age, ED has been shown to compromise 
overa ll quali ty of li fe and is assoc iated with depression, anx iety, and 
loss of se lf-es teem2 To date, the diagnosis of ED is typically made 
on hi story and physica l exam3· 4. In recent years however, increased 
understanding of the hemodynamics invo lved in vascul ogeni c ED 
has lead to the development of a number of di ffe rent di agnosti c tests. 
These include penil e brachial index, intracavernous pharmaco logic 
testing, penile tumescence monitoring, co lor duplex ultrasonography, 
cave rnosograph y and pharmaco logic cave rn osometry, penil e 
scintigraphy, and selecti ve pudendal arteriography! · 5 Whil e each 
yields inforn1ati on of some diagnost ic va lue, there is yet to be a 
single test or "gold standard" for diagnosis of EDJ Much of thi s 
could be due to that fact that many of the current tests are complex , 
ex pensive, invasive, and often inaccurate. Given these limitations, 
and especiall y in light of advanci ng effi cac iou ora l therapies readily 
ava ilable, some spec ia li sts argue that these tests should be reserved 
for pecial cases of ED where a diagnos is is important or urgery is 
required . However, an oppos ing view is that a minimall y invas ive 
and cost-effective test may till be of va lue in completing the 
appropriate management of a pat ient with suspected va culogenic 
ED6. 
Thi s stud y was unde rtake n to examin e nea r- infra red 
spectroscopy (NlRS) as an approach to study penile blood flow and 
thereby explore a potenti a l nove l diagnosti c tool for assess ing 
vascul ogeni c ED. N IRS has emerged as a new technology within 
recent years for monitoring blood fl ow non-invasive ly and sa fe ly. 
The techno logy uses photons of light in the near infrared spectrum to 
assess concentration changes of oxygenated and deoxygenated 
hemoglobin in ti ssues6. It can provide information concerning both 
oxygen saturation and re lati ve blood vo lume changes within the 
organ of interest. A lthough N l RS has been widely used to assess 
muscle and cerebral blood flo w, it use in the assessment of penile 
blood flow has been limited6. We exam ined the use of N IRS to 
detect penile blood flow and to determine if increases in oxygenated 
hemoglobin (0 2Hb) concentrations corre late with erections. 
METHODS 
Two groups of men were exam ined. Group I cons isted of I 0 young 
men with no erecti le difficulties, mean age 19 years (range 18-22). 
These men allowed us to determine the technica l aspects of NIRS 
monitoring on the penis (i.e. optica l sensor placement and how to 
secure the sensor) and the feas ibility of assessing penile blood flow 
with visual sexual stimulation (YSS). Group 2 consisted of 12 men 
with prostate cancer undergo ing a bilateral nerve sparing radical 
pro tatectomy (RP). Mean age of the patient was 55 years (range 
44-66) . These men underwent N IRS with YSS preoperatively and at 
3 months postoperati ve ly with and wi thout 20 mg of vardenafi l. Each 
completed a va lidated psychometrica ll y va lidated questi onnaire li EF 
(Internati onal Index of Erect ile Function) pre and postoperative ly. 
During N IRS testing each man was asked to assess if an erecti on 
occurred during the YSS. 
RESULTS 
With Group I we were ab le to create a re-usable NIRS optical sensor 
probe which wa taped to the penis . In 7110 of the men an erection 
occurred with YSS and wi th NIRS testing. 0 2Hb concentrati on 
increased in a ll 7 men (Figure I). In Group 2 the mean II EF 
preoperati ve core was 25 (range 5-30) and the postoperative score 
was 11 .1 (range 1-26). With N!RS testing preoperatively without 
va rdenafi l, 8112 men felt they had some erect ion wi th YSS, and in 
7/8 of these men there wa an increase in 0 2Hb concentrati on. In the 
one in whi ch NIRS was unsuccess ful the erecti on was minimal. In 
Figure I. Norma l males with good erections after VSS. Increase in 
02Hb. 
thi s same group, 9/ 12 men with N IRS testing showed increases in 
0 2Hb concentrati on with YSS, 2 of which fe lt they had no erection 
(Figure 2). When vardenafi l was given preoperati vely wi th NIRS 
testing, 12112 men fe lt they had some erection and I 0/12 of the e 
men had an increase in 0 2Hb concentration. Postoperati vely wi thout 
vardenafi l on N IRS testing 2/12 men fe lt they had some erection and 
7/ 12 men were found to have increases in 0 2Hb concentrati on 
including the 2 men that had some erection. When vardenafil was 
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added postoperati vely 7/12 men fe lt they had some erecti on and 7112 
men had increa es in 0 2Hb concentration on NIR te ting (5 
pati ents wi th an erection and 2 wi thout). There was a rapid rise in 
0 2Hb concentration in men wi th excellent erection . 
J- HCITI)O:JB - (])y•cm):Jiron v i'!OCI"fcm -""~m 
20 
~ .... ,.,......, 
:J 10 
0 ~ E 2 .. c 
0 
f! 
~ 
:: 
c 
0 
·10 u 
f 
0 
.. 
c , 
.r: 1'0 u 
..fJ 
10J 100 ;m ~f)"" 'j()Q 
Elopoed Time jrnil) 
F ig ure 2. Patient preop without vardenafil with no erection and no 
increa e in 0 2Hb. 
DI SC SS IO 
To date, management of a pati ent with suspected ED is often centred 
on a goa l-ori ented approach4•7•8• Treatment selection i ba ed on 
pati ent preference following a thorough di cussion with a treating 
physician regarding therapeuti c options with minimal diagnosti c 
te ting. Reason for this empirica l approach probably stem from the 
relati vely safe and highly effective medicati ons currentl y ava ilab le 
for ED9 De pite thi s, studie completed on ou tcome ana ly e of the 
goa l-directed approach, often indicate low pati ent sati faction 
rate JO, IJ . l2. In part , thi s could be due to the fact that without a 
thorough under tanding of the et iology and pathophysiology of a 
given patients D, commonly preferred therapie may be ineffective. 
Perhaps a di ag no is-based, (pathogene i - pec i fi e) trea tment 
approach to pati ents with suspected ED may yield better outcomes 12 
In thi preliminary tudy, we demon trated that NIR can be 
used to as e penile bl d flow with ex ual timul ati on. 
Accordingly, we perfom1ed a eries of penil e IRS studies on both 
healthy subject , and on patient presenting with va ri ou degree of 
· D. Upon ana ly i , a ri se in OzHb concentration on N I R wa found 
to correlate very well to pati ent perceived erecti ons. The results from 
thi s early in vestigati on suggest that it may be clinica lly u eful ~ r the 
practicing urologi t. The appea l of thi s modality i further upported 
by its perceived advantage : low equipment cost, tran p rtability, 
operator non-dependence, simple operati on, and sa fety 
Desp ite these indicati on for a di agnosti c role of a peni le IR 
device, the criti ca l measure of the clinica l utility of any new 
technology re t on its ability to direct appropriate therapeuti c 
management. Given our limited sample size, our study wa unable to 
examine whether peni le NIRS can accurately di scern blood fl ow 
profile di fferences between vasculogenic and non-vasculogcnic ED. 
Looking ahead, further studie are needed to establish diagnosti c 
ranges that identi fy p ychogenic/neurogenic (non-va cul ogenic), 
mild vascul ogeni c, and severe vasculogenic cau es of D. A we ll , 
more studies are needed to correlate NIR te ting with Doppler 
studies 13 • 
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Surgical treatment for articular cartilage 
injuries in the athlete's knee 
Sandeep Dhaliwal (Meds 2013), Brennan Ballantyne {Meds 2014) 
Faculty Reviewer: Dr. Marie-Eve Lebel, MD {Department of Orthopaedic Surgery) 
A rticular cartilage injuri e of the knee are frequently observed in athletes partaking in hi gh-impact sports, particularly at the competiti ve collegiate, profess iona l, and world-class leve1. 1•2 
Additionally, increas ing recreational partic ipation in pi vot ing sports 
such as footba ll , basketball , and occer has been associated with a 
rising number of sports-re lated articular cartil age injuries in the 
genera l popu lati on3 .4 When left untreated thi s type of injury re ults 
in long-tenn dec line in athletic perfonnance5 and predi sposes the 
athl ete to earl y joint degenerati on6 The purpose of med ica l 
inte rvention, therefore, remains twofold: I) returning the athl ete to 
pre-inju ry perfonnance; and 2) pre erv ing long-tenn knee function to 
ensure a healthy lifestyle can be maintained as the patient ages. 
Articul ar cart ilage is a we ight-bea rin g connecti ve ti ss ue 
consi ting of chondrocytes whose primary function is to secrete 
extracellular matrix. Due to the a neural and avascul ar nature of thi s 
ti ssue, damage caused by inju ry or pathogenes is results in very 
limited abi li ty for self-repa ir7 In this manner, treatment of articular 
cart ilage injuri es in the athl etic popu lati on presents a signifi cant 
therapeuti c cha llenge. Analgesics, anti-infl ammatory medi cati ons, 
activity mod ifi cati on, change in body weight, rest and phys ica l 
therapy may provide partia l symptomatic re li ef, but they do not 
restore damaged cart il age to its natural state. Surgica l procedures 
such as total joint replacement may he lp re li eve joint pain , but pose 
significant limitations to younger patient w ishing to pursue vigorou 
physica l activity. Additi onall y, surgica l debridement remains a 
potenti al option, but it too is not ideal as it fails to restore carti lage . 
Therefore, substant ia l efforts have been devoted to the development 
of biologic methods for restoring degenerating articul ar cart il age. 
Based on the source of the cartil age repa ir tissue, new techniques can 
be broadly c lass ifi ed as: 1) marrow stimulati on-ba ed techniques; 2) 
osteochondra l transplantation techniques; and 3) cell -based repair 
techniques. Moreover, the development of new treatment regimens 
present prom ising scientifi c and clinica l excitement for the treatment 
of articu lar carti lage injury. 
MARROW STIMULATION 
Developed in the early 1980s, a su rgical technique known as 
mi c rofracture is a cost-effective, minimally in vasive , and 
uncomplicated procedure wide ly used to treat ca rtil age inj ury in the 
ath lete's knee. Microfracture hinges on the penetrati on of the 
subchondral plate w ith an awl or drill and filling of the cart ilage 
defect to take place by a blood c lot that contains pluripotent marrow-
derived mesenchymal stem ce ll s. These ce ll s pro liferate and 
differenti ate to produce a cartil ag inous repa ir ti ssue that eventually 
fill s the chondra l defect. ·9 The procedure is carried out by plac ing 
the pati ent in a supine position on the operating room table and 
admini stering a lower extremity or genera l anaestheti c. A femoral 
nerve block for postoperative pa in relief may also be used.10 The leg 
is prepped, draped and has a tourniquet applied which can be inflated 
if arthroscopic visua lizati on becomes difficult due to intra-a rti cular 
bleeding. The orthopaed ic surgeo n ca rri es out a thoro ugh 
arthroscopic diagnostic exam inati on whereby the lesion is identifi ed 
and debrided of a ll loose or margina ll y attached ca rtil age using an 
arthroscopic shaver and a curette. This leaves a tab le rim of 
cartil age su rrounding th e defect whi ch is an idea l full-thickness 
border to provide a degree of protection to the regenerating tissue 
that will form in the treated les ion.11 A ca lc ified cartilage layer 
typ ica ll y remai n With animal studi e showing that complete 
remova l is cruc ial to ensure proper repa ir, 12 the ca lc ified cartil age 
layer is removed by the u e of a curette or a burr. After preparati on 
of the lesion i complete, an arthroscopic aw l is employed to make 
multipl e holes (mi crofractures) in the exposed subchondra l plate. 
Holes are spaced 3-4 mm apa rt to ensure that the subchondra l bone 
maintains adequate structural integri ty, and a depth of 4-5 mm, or 
Until fat dropl ets are visibl y seen coming from the marrow after 
tourniquet de fl ati on, is typically achieved. 
OSTEOCHONDRAL TRANSFER TECHNIQUES 
Osteochondra l grafts of auto logous or a ll ogenic ori g in rely on 
transplantati on of intact mature hya line cartil age containing viable 
chondrocytes attached to subchondral bone. Although both 
auto logous and a ll ogeni c modalities represent complementary 
paradigms des igned to restore the characteri stics of nati ve ti ssue, 
each pose their own set of unique chall enges w ith regard to ti sue 
ava il ab ili ty and safety. Generally, autografts are indicated fo r 
re latively sma ll (< 2cm) focal articu lar lesion of the femoral 
condyles .13 Donor-site harvest is carried out from regions of less 
we ight-bea ring tructures in the knee such as the medial and lateral 
trochl ear ridge, the intercondylar notch, or the sulcus te1mina li s of 
the lateral femora l condyle.14 Historica lly these areas were 
considered non-weight bearing, but recent reports have demonstrated 
that the e areas do bear significant weight and can lead to increased 
donor-site morbidity, such as osteoarthriti s .13 Advantages of an 
auto logous approach inc lude immedi ate ava ilabili ty, relatively low 
cost, and nonanti genic and osteogeni c cart il age properties that result 
in uccessfu l osteointegration . However, auto logous graft sources 
are self- limited in th ei r maximal surface area, and donor-site 
morbid ity can add a sign ifi cant disease burden to the pati ent. On the 
other hand , osteochondra l all ografts are indicated for the treatment of 
medium to large a11icul ar le ions and are hi ghl y versatil e in treating 
very complex or multiple lesions without inducing any donor- ite 
morbidity. 13 Drawbacks to the allograft approach incl ude scarcity of 
donor ti ue, potentia l ri sk fo r disea e transmi sion, a well as 
fin ancia l and logisti ca l is ues regarding graft procurement. 
Autograft transplantati on can be perfonned arthroscopica ll y or 
through a tandard "open" arthrotomy approach. The patient 's knee 
is prepped and a di agnosti c arthroscopy i undertaken to debride and 
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mea ure the cartilage defect. Donor grafts are extracted using a T-
handled recipient harvester. Plug sizes fo r the harvester vary from 4 
to I 0 mm depending on which commerc iall y ava ilable instruments 
are used during the operation. 14 After planning the number, size and 
placement of spec ific grafts, the harvester is aligned perpendicular to 
the donor cartilage and tapped to an appropriate depth . Once tapped, 
the harves ter chi se l is di engaged by rota ting or "gentl y 
toggling" (depending on which system is used) the handle in order to 
amputate the graft. The recipient ocket can be prepared using a core 
or drill. In general , a socket is created in the area of the defecti ve 
cartil age by u ing a slightly maller circumference T-handled 
harvester tapped to a depth of equal or greater length than the donor 
plug extracted. Finally, the graft i implanted under direct 
visuali zation using a delivery tube and tapping the impactor with a 
gentle force. Once the graft is in place, the delivery tube is removed 
and any resulting margins on the articul ar surface should fill with 
fibrocartilage . 
Converse ly, usi ng an open inci ion , osteochondral all ograft ing 
commences by establishing the size of the host knee defect using a 
sizi ng cylinder. A sizer is placed over the entire les ion and a 
guidewi re i dri ven through the center of the sizer perpendicu lar to 
the femoral condyle su rface . The condyle is then scored to the 
subchondral bone usi ng an appropriately sized circumferenti al cutter 
(reamer) placed over the guidewire. The reamer is typically drilled 
into the defect to a leve l of 8- 10 mm below the nati ve cartilage 
urface. 10 Employing the same sizer used on the host knee, the 
all ograft is sized and reamed in the same area of the condyle where 
the ho t lesion is located. To avoid any height mismatch, the graft is 
carefu lly cut with an osci llat ing saw to an appropriate height and the 
edges are sli ghtly bevelled to fac ilitate placement into the ho t 
defect. Final ly, a dil ator is impacted into the recipient site in order to 
achieve sli ght dilati on (0.5 mm) which enables graft placement using 
di gita l pressure. Additional fi xation can be achieved using screws or 
pins although it is usually not required with thi s method. 
CELL-BASED REPAIR TECHNIQUES 
Initi a ll y described in the mid-90s, autologous chond rocyte 
implantation (ACI) plays a major ro le in treating large full-thickne 
chondral injuries.15 AC I i a dual-stage procedure which utili ze the 
first- tep to harvest chondrocytes, and then a second- tep to re-
implant them following in vitro culture. The initial-stage involves an 
arthroscopic examinati on to enable full assessment of the inju ry to 
estab li sh the patient 's suitab ly for the procedure. If it i appropriate 
to continue, sli ces of cartil age are harvested with a curet. The 
femoral trochlea and intercondylar notch are recommended a 
harve t ites based on limited complicati on and morbidi ty being 
associated wi th the use of those areas.16 After the sli ces are removed 
they are placed in a sterile vial and tran ported to the laborator; 
where chondrocytes will be cultured. The second-stage of A I i 
ca rri ed out u ing an arthrotomy to achi eve adequate exposure. The 
defect i debrided with care being taken to ensure that bleeding from 
the subchondral bone i minimal as it can introduce stem ce ll s and 
fibroblasts into the defect. The defect is measured and a template 
using steril e paper is made. A peri o Lea l fl ap from the proximal 
medial tibia is obtained using the templ ate. This fl ap is harve ted 
and then sutured to the cartilage rim of the defect and the border is 
sea led using fibrin glue. The cultured chondrocytes are then 
aspirated into a syringe and are injected under the periostea l graft.1 7 
CLINICAL OUTCOMES AND EMERGING TECHNOLOGY 
Numerous systemati c studies have elucidated improved knee 
function and increa ed activ ity scores for all three types of arti cul ar 
cartilage repai r strategies outlined above. Only recently, however, 
has m~ta-analysis comparing differen t repair techniques on returning 
the InJured athlete to sports participation become available. Two 
separate reviews sugge t better outcomes for patients undergoing 
autologous chondrocyte implantation and osteochondral transfer 
techniques versus microfracture. 18·19 Based on a review of 20 studies 
and 1363 patients, return to sports participation was observed in 73% 
of athletes with the highest occurring in those who underwent 
o teochondral autograft transplantation . On the other hand, 65% 
were actuall y deemed to have been able to return and perform at a 
pre-i njury level and thi s was best achieved with autologous 
chondrocyte.19 As it pertains to adolescent athletes, evidence in the 
literature is scarce, but initial reports have suggested that better 
results are observed with autologous chondrocyte repair.20 It appears 
that numerous factor , uch a age, level of play, lesion size, and 
duration of symptoms, can impact the clinical outcomes observed in 
thi s pati ent populati on. 
Several report depicting functional outcomes,21 as well as 
return to athletic competition22 following microfracture can be found 
in the I iterature. Despi te initial improvements, however, there is 
confli cting evidence regarding long-term results as some studies 
suggest that deterioration of knee function occurs in 47% to 80% of 
athl etes 24 months following surgery.19·21· 23 These limitations have 
prompted inve tigation of new technologies to enhance the results of 
ex isting microfracture techniques . For example, the development of 
a dehydroepiandrosterone ulphate (DHEA-S)-releas ing rod that can 
be implanted into the microfractures bas shown promise in 
improving cartilage in animal model .24 Other efforts have revolved 
around the addition of growth facto rs to promote chondrogenic 
differentiation , or inhibiting the potential negative effects of 
cytokines23 Final ly, the creation of a bioadhesive using choindroitin 
su lphate as a primary component ha yie lded promising re ults in 
clinica l triaJs2s 
In an effort to improve clinica l outcomes, new and innovative 
techniques are rapidly advanci ng the field of articular ca rtil age repair. 
For instance, to avoid the problem a ociated with osteochondral 
auto- or a llograft , yn thetica ll y manufactured bioresorbable 
caffolds have been developed a ubstitute grafts2J Principles of 
scaffolding have also been app lied to autologou chondrocyte 
implantation \ hich pro ide a mechanism of de li ve rin g 
chondrocytes into a lesi n during a ingle- tage procedure without 
nece si tating ex vivo chond rocyte cu lture and expansion.26 During 
th1 s procedure, the harve ted carti lage is fragmented and then 
embedded into a resorbable caffo ld which is then implanted into the 
knee. Other techniques currentl y being explored include the use of 
g~n e therapy to improve cartil age repai r by tran fecting chondrocytes 
w1th BMP-2, BMP-7 and IFG- 1 and neocartilage harvesting of 
JUVenile chondrocytes from prepuberta l and fetal human cartilage_27 
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Computed tomography (CT) based calcium 
scoring in the diagnosis and prognostication of 
coronary artery disease (CAD) 
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Faculty Reviewer: Dr. Aash ish Goela, MD MSc FRCPC (Depa rtment of Medical Imaging) 
I nvented by Si r Godfrey Hounsfield in the 1970 , computed tomography (CT) has greatly trengthened the arsena l of imagi ng techn o logies th at is ava il ab le to ph ys ic ians to detect, 
prognosticate, and treat d isease. T he fundamenta l princip le 
underl ying CT canning is the ex po ure of biological ti sue to 
rotating fin e beam X-rays, fo llowed by the detecti on and process ing 
of the radiati on that these ti ssues attenuate to create a computeri zed 
image1. The two major types of CT scanning are heli ca l CT and 
conventiona l non-overlapp ing CT. Since its introducti on, variou 
enhancements have been made to T technology which has a llowed 
appl ication aero varied medical fie lds. In cardiac imaging, 
coronary CT angiography has recentl y risen to the forefront. A it i 
a newer technology, data in the li te rature lags behind the well -studi ed 
methods to quanti fy the amount of ca lc ium inside coronary arteries 
using infonnation obtained from cardi ac CT scans, known as cal cium 
scoring2 . ln th is arti cle, we ex plore the use of thi s speciali zed CT 
technology and highlight its advantages and limitations in the 
diagno i and prognostication of coronary artery di sease . 
CT BASED CALCIUM SCORING 
In coronary arteries, CT based calcium coring methods quanti fy 
ca lcium as a parameter tenned coronary artery ca lc ifi cation (CAC)3. 
Ca lc ium scoring is used to evaluate coronary artery di ease since 
calc ium bui ld up in pl aques is a key process in atherosclero is. It 
should be noted that there is ev idence non-ca lc ified plaques areal o 
important , however, they are not eva luated by thi s method and are 
thus outside of the cope of th is review. lectron beam CT ( BCT) 
ha been a popular method for the a e sment of coronary calcium 
since its development in the 1980 . Nowadays, ca lci um scoring can 
also be perfo rmed with multidetector or multi s lice CT canners 
(MDCT and MSCT). There is some agreement that the ca lc ium 
scores obta ined from both methods are sim il ar, though thi has not 
been extensively studi ed4. Vari ous methods have been used to 
compute ca lc ium scores ; for exa mple, the Agatston score ass igns a 
weighted va lue ba ed on the hi ghest density o f calc ifica ti on in the 
plaque and then multipli es thi s by the area of ca lcifi cati on5. uch 
scores for all ca lcifi cations in all CT li ce taken are summed up to 
prov ide a CAC score for a ll the coronary arteri es. 
Due to certain limitati ons w ith Agatston scoring, mo t notabl y 
inconsistent inter-sca nner comparability, newer methods such a the 
vo lume score and ca lc ium mass score were developed and compared 
with the Agatston score. Some studi e indicate that these methods 
may be equi va le nt to th e Aga ts to n me th od in te rm s of 
reproducibility6. A more recent method of ca lc ium scoring is known 
as the lesion specific calci um score in which more specifi c 
parameters related to each ca lcifi ed le ion are included in the fin a l 
ca lcium score, such as w idth, density and di stance from major 
coronary arteries7. There is emerg ing evidence to indica te that the 
les ion-speci fi e ca lci um scoring meth od maybe more accurate th an 
the Agat ton method for some purpo es; for example, the sensitivity, 
specific ity, and accuracy of the le ion specifi c calc ium score method 
were shown to be superior to the traditi ona l Agatston core in 
detecting angiographically confi nned obstructi ve coronary artery 
di ease8 
CORONAR Y ARTERY CALCI FI CATION (CAC) AND 
CORONARY ARTERY DISEASE 
Many stud ie have shown the association between CAC and 
coronary artery d i ease a de tected by hi topatho logica l or 
ang iograph ic methods . For example, one hi stopatho logical study on 
autop ied coronary arteries showed that the EBCT ca lc ium scores 
correlated well wi th plaque area9. A clin ical study of more than 700 
pati ents showed that EBCT ca lci um coring had 95% sen iti vity in 
pi cking up ang iographica lly ignificant coronary artery di sease10. 
CAC has also been tud ied in re lati on to myoca rdi a l ischemia. 
Myocard ial i chem ia most often mani fe ts s ilently, and thi can be 
detected as stre -induced i chemia wi th stress testing. One studyl 1 
showed that the li ke lihood of tre -induced myocard ia l ischemia 
increa ed wi th a higher CAC core, a lthough the maj ori ty of patients 
(78%) with detectable CAC did not have stress-induced ischemia 
suggesting a poor pos itive predictive va lue of prognosi with CAC 
coring. A report from the pro pecti ve cohort study known as the 
multi ethni c s tudy of ath e ro cle r os is (M ESA) eva lua ted the 
re lati onship betwee n CAC and myoca rdi a l ische mi a in an 
asymptomatic population12. Thi tudy showed that the coronary 
va odil atory re ponse (myocardia l blood fl ow with tre ) wa 
reduced with a higher CAC, but the re ting myocardi al b lood flow 
was not affected by increa ed AC. These studi e provide some 
indicati on that CA maybe associated w ith impa ired myocardia l 
perfu ion in a subclinica l atheroscleroti c state . Overa ll , there is a 
good body of ev idence to uggest that CAC i associated with 
structura l and functiona l coronary artery di sease . 
PROGNO T IC VALUE OF CAC 
Studi es have a sessed the prognosti c value of CA m both 
symptomati c and asymptomati c pati ent popu lati on . There i 
reasonable ev idence to indicate that AC has good prognosti c value 
in asymptomatic pati ents. For example, a study of more than 5000 
low- intermedi ate ri sk,_ midd le-aged adu lts over a 3 year fo llow up 
pen od found that h1 gher EBCT CAC sco res at ba eline were 
assoc iated with a hi gher ri sk o f developing cardiac events later on in 
both gender 13 Another study o f more than 1000 patients over a 19 
month fo ll ow up period showed that higher cut-off leve l for EBCT 
CA . scores were associated with better specific ities for predicting 
ca rd1 ac event 14 . Incrementa l progno tic va lue o f EBCT CAC wa 
observed, in addition to that prov ided by conventiona l cardi ac ri sk 
factors. 
12 UWOMJ I 80 :1 I Spring 2011 
One study in a symptomatic patient population con i ting of 49 1 
parti ci pants referred for coronary angiography found that EBCT 
CAC scores were moderately predictive of ang iograph ica ll y 
confirmed coronary artery stenoses and that hi gher scores were 
assoc iated with a hi gher incidence of coronary artery re lated card iac 
events 15. A simila r study 16 on patients referred for coronary 
angiography followed up after an average time of 7 years fo und that 
among conventi onal risk fac tors and EBCT CA , only EBCT CAC 
(ri sk ratio 1.72) and age (risk ratio 1.88) were predictive of future 
hard cardiac events (hard events include non-fatal myocardial 
infarction and cardiac death) . Furthermore, pati ents with an EBCT 
CAC score of less than I 00 had significantly hi gher event-free 
surviva l rates 16. Taken together, the prognostic va lue of CAC has 
been shown to have a high negative predictive va lue and a moderate 
positive predicti ve va lue for major adverse coronary events (MACE). 
Thus, CAC shows promise for a iding in ri k stratifi cation. 
LIMITATIONS OF CALCIUM SCORJNG 
Although the above di scuss ion has highlighted the va lue of ca lc ium 
scoring in detecting and providing prognosti c information about 
coronary artery di sease, certain caveats of ca lcium scoring exist 
For example, some results suggest that there is a threshold level of 
calcium accumulation beneath whi ch EBCT CAC is not predicti ve of 
plaque area or everity 17• Furthermore, studies have reported that 
EBCT CAC has very good sensiti vity for picking up significant 
angiographic stenoses (greater than 50%), but only moderate 
specificity 18. This was confirmed by a consensus document re leased 
by the American Coll ege of Card iologyl 9 in which , based on a meta-
analysis by the working group, the sensitivity and pec ifi city of 
EBCT in detecting coronary artery stenoses were 91 % and 47% 
re spectivel y. Studies have also evaluated whether treating 
asymptomatic pati e nt s with hi g h calcium sco res with 
pharmacotherapy improves outcomes. For example, the St. Francis 
heart study randomized controlled tria l showed that treatment of 
patients having high ca lcium scores with statins and antioxidants did 
not reduce the progression of coronary ca lcification or the rates of 
atherosclerotic cardiovascu lar disease events20 . 
Interestingly, another randomized controlled tria l showed that 
using results from EBCT ca lc ium scores to moti vate behavioural 
change was not successful , as reflected by a lack of improvement in 
composite cardiac ri sk measured by I 0 year Framingham risk 
scores2 1. This rai ses concerns about the uti lity of EBCT calcium 
scoring in being an effective screening tool that affects outcomes, but 
more studies are required in thi s regard . In addition , there are 
practica l, unreso lved concerns about the application of EBCT CAC 
from a screening perspective; for example, its cost effectiveness and 
the negati ve effects associated with false positi ve te ts and radiation 
exposure are potentia ll y worrisome. 
CLINICAL RECOMMENDATIONS FOR USE OF CALCIUM 
SCORING 
The American Co ll ege of Cardiology Foundation (ACCF) publi shed 
a consensus document in 2007 to synthes ize the evidence and make 
recommendations regarding the clinical use of CT based calcium 
scoring3. For example, one of the recommendations states that it is 
helpful to use CAC to ri sk stratify asymptomatic patients that have 
an intermediate I 0 year ri sk of developing cardiac events (1 0-20%), 
since this may affect how aggressively patients are managed. 
However, this use of calcium scoring is not recommended for low 
risk (< 10%) asymptomatic patients since these patients are likened to 
the general population and there is no evidence to support screening 
the general population with CAC. CAC measurements were also not 
recommended for high risk (>20%) asymptomatic patients since 
intensive medical therapy is already suitable for these patients. Also, 
owing to insufficient evidence, a recommendation was made to not 
( 
reduce treatment intensity of intermediate ri sk patients that had zero 
ca lc ium scores. Furthermore, the recommendations caution against 
extrapolat ing findings to populat ions that have not been we ll studied ; 
the ev idence appear strongest for Caucas ian, non-Hispanic men. 
CONCLUSION 
Despite some limitati ons m its spec ificity and concerns about its 
applicability to pati ents of varyi ng ethni c iti es and ri sk statuses, CT 
based ca lc ium coring of coronary artery ca lcificati on has emerged as 
a useful tool that provides added prognostic and screening va lue, 
especia ll y in asymptomatic patients with intermed iate coronary heart 
di sease ri k . G iven the preva lence of coronary a11ery di sease and its 
unpara ll e led impact on mortality and morbidity, better and innovati ve 
methods of cardi ac di sease screening and prognosti cation , including 
ca lci um scoring, wi ll become increasingly important in providing 
patient-centred care. 
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T he goa l of this arti c le is to di scus DTC genetic testing in tenns of the process of testing, the current regul ati on of the indu try in Canada and the effect the resu lt ing informati on can 
have on managing individual and populati ons in hea lthcare. This 
w ide-rangi ng and rapidly evo lving topic ex tends into the fie lds of 
genetic , ethics, law and business, each of whi ch have been 
addressed in the following fash ion: the accuracy of testing, the 
predi cti ve va lue of the results, the possib le effects that the test will 
have on the consumer and fina ll y the effect that the personal geneti cs 
industry w ill have on physic ian practice and soc iety. Due to the rapid 
evolution of the field , testing kits can now be purchased for a littl e 
as three hundred do ll ars, making personal genetic testi ng highly 
affordab le and accessible. 
THE ACCURACY OF THE ASSAY 
DTC gene testing compani es such as 23andme, deCODEM E, 
Navigenics and K.nome (the ' main players' in the current market1) 
are private labs governed by the laws in their jurisdiction . In Ontario 
that licensing body is the Laboratory and Specimen Co llection 
Centre Licensing Act (LSCCLA). However, the majori ty of these 
corporat ions are Ameri can and are hence regul ated by the Centers for 
Medicare & Medi ca id Serv ices (C MS) under the Clinica l Laboratory 
Improve ment Amendments (CL!A). Recentl y there has been 
concerns about " fau lty lab data ana lyses, exaggerated c lini ca l claims, 
fraudulent da ta , poo r c linical study des ign and a lack of 
tracea bili ty"2. The United States Government Accountabi li ty Office 
recently reported that when samples of DNA were sent to four 
different DTC testing companies "different companies often provide 
different results for identical DNA"3. Interestingly, the test ing kits 
themse lves are not considered medica l dev ices and are hence not 
regulated by the Food and Drugs Act4.5. Additionally, the maj ori ty of 
genetic tests are offered as in-house laboratory serv ices and are 
similarl y not regulated by the federal governm ent through the Hea lth 
Protection Branch or Therapeutic Products Program6. 
THE LINK BETWEEN TESTED GENES AND DISEASE 
In contrast to geneti c testing in a cli nica l context, pri vate genetic 
testing a lso examines more ' personal' genetics traits. According to 
the website fo r deCODEME you can "di scover your genetic ri sk for 
47 di seases and traits ranging from Heart Attack and Diabetes to 
A lcohol Flush Reacti on and Male Pattern Baldness"7. However 
di sc la imers also state the results may have poor predicti ve va lue 1 and 
are not considered di agnostic, leading customers to questi on the 
finan cia l va lue of uch test results. Nonethe less, the e compani es 
g ive the ir customers information about the research that links these 
polymorphi sms to increased probability of developing a g iven 
di sease. 
THE EFFECT OF THE TEST RESULT ON THE CONSUMER 
Whil e some DTC compani es offer ove r-th e- pho ne geneti c 
co unse lling with the results, it is important that a ll customers 
understand the information in a contextua li zed manner. Thi s require 
understand ing of concepts such a re lative and lifetime risk of 
di ease. Physicians have also expressed concern over so ca ll ed 
' geneti c determini m', where the indi vidual negates environmenta l 
ri sk factors which are contributory to the di sease in favour of the test 
re ults8. For exam ple, a pati ents' ri sk of heart di ea e is more 
re fl ecti ve of the ir weight, blood pressure and/or cholestero l than 
genetic factors4 . Another ethica l concern is testing for conditi ons 
where there is no viab le treatment or preventati ve measures. 
Advocates of DTC testing point to studies such as the REVEAL 
study, which showed that di sclosure o f a genetic tra it predisposing 
patients to Al zheimer 's di sease "did not result in s ign ifi cant short-
tern, psychologica l ri sks" compared to those that were not tested9. 
Pri vacy concerns a lso ex ist about third party di sclosure of data, 
e pecially in regards to hea lth and li fe insurance, where thi s deta il ed 
inforn1ation could lead to genetic di scrimination. Whil e company 
poli cy is genera ll y not to di sc lose information without explic it 
consent of the customer, the infonnation itse lf is not protected to the 
same standard as infonnation covered by the US Hea lth Insurance 
Portability and Accountabili ty Act (HIPAA)10•11 . If a customer 
di scovers that they are pos iti ve for a mutati on and fa il to di sclose it 
to the ir insurance company, it may serve a grounds for vo iding 
po licy if the insurance company finds a way to access the 
infonnation8•11 . Sim ilarl y, the Canadi an Human Rights Act does not 
conta in a clause protecting aga inst geneti c di scrimination, though an 
amendment i currently under considerati on in the House of 
Commons (Bill C-536). On the other hand, Americans are protected 
from such di scrimination by the Genetic Inform ation on-
di scrimination Act (G INA) whi ch doe not apply to Canadians using 
the US based compani es. 
THE ROLE OF THE HEALTHCARE SYSTEM 
Ontario's Regul ated Hea lth Profess ions Act st ipulates that a 
hea lthcare professiona l i responsib le for "communicating to the 
indi vidua l o r hi s o r he r perso nal representati ve a diagnos is 
identi fYi ng a di sea e or di sorder as the cause of symptoms of the 
indi vidua l in circumstances in which it is reasonably foreseeab le that 
the indi vidual or hi or her per ona l representati ve wi ll re ly on the 
di agnosis" 12 Does the genetic ri sk assessment offered by these 
pri vate ly owned companies count as a diagnos is? The companies 
explic itl y state that their products are not diagnosti c o r are substitute 
for medi cal advice and that a ll concerns ari sing from the test should 
be referred to your hea lthcare prov ider. The onus then lie on the 
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fa mily practiti oner to interpret the information, a burden that could 
become substantial according to a study by McGuire et al where 78% 
of respondents sa id they would con ult their family doctor about 
results of commercial ge netic test4 . This increased burden on the 
hea lthcare system is furth er complicated by the fact that famil y 
physic ians are often not trained in geneti cs counse lling and may not 
be equipped to deal with thi s extensive genetic inforn1ation. 
CONCLUSION 
In 20 I 0, the FDA sent regul at ion letters to five American commercial 
genetic testing companies stating that their device is regul ated " . . . 
under secti on 20 I (h) of the Federal Food, Drug, and Cosmeti c Act 
(the Act), 2 1 U.S. C. 32 1 (h) because it is intended for u e in the 
di agnosis of di ease or other conditions or in the cure, miti gati on, 
treatment, or prevention of di sease, or is intended to affect the 
tructure or function of the body."; it went on to state that the product 
is cia sift ed a a medica l device under the Medi ca l Device Act and as 
such require premarket approva l13 Increas ing regulati on has been 
occurring in both the United tates and many European countries out 
of concern for inaccurate or mi leading test results14 
However, supposing the tests are accurate and re lati ve ly spec i fie 
the next logical question is whether the knowledge of ri sk factors 
will translate into better outcomes for patient : reduci ng risk, ea rli er 
creening, prophylactic measures and, in orne cases, influence on 
famil y planning6. It i difficult to assess thi s as the industry is 
relatively new and there is no follow up after the company di close 
the re ult to the customer. Without counse lling it may be difficult to 
put the ri k into context for the individual patient and an over or 
underesti mati on could be delete ri ous to a pati ents' hea lth4 
Proponent argue these te t champion patient autonomy and to limit 
access to one's own genome is paternalistic whi le detractors are 
concerned the patchwork regul ation does not protect customers 
purchasing these products. With expanding use of these services the 
effects of thi s pl ethora of information, both posi ti ve and negati ve, 
will be become more apparent. 
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A s healthcare costs escalate and the public maintains high expectat ions about health ervice delivery, the sustainabi li ty of our current public system ha become untenable. In 20 I 0, 
health expenditures compri sed 11.7% of Canada 's GOP and 192 
billion dollar were spent on hea lthcare.1 Furthermore, Canada 's oft-
cited agi ng populati on-which consumes 44% of a ll hea lthcare 
do ll ars-continues to grow. In 2005, 13% of Canadians were age 65 
or o lder; by 2036, that figure is expected to reach 24.5%2 As 
policymaker struggle with broad healthcare reform, they are asking 
hard questions about the margi nal returns of further spending on 
sickness care. For their part, c lini ca l managers and c lini cian- leaders 
are worki ng to reorgani ze the delivery of hea lth services, promote 
evidence-guided decision-maki ng, and create a culture of inter-
professiona l co ll aboration and qua li ty improvement. 
There is increasing pressure to promote cost-efficiencie in the 
hea lthcare system, and hea lth information technology (IT) has 
enormous potential in that regard . Ev idence suggests that such 
innovations can enhance the effic iency, cost effectiveness, quality, 
and safety of hea lthcare delivery.3 And as the face of hea lth human 
resources changes, with the adoption of co llabo rative multi-
disciplinary models of care, sharing of health information between 
providers is all the more cruc ia l. 
As of March 20 10, an e lectronic hea lth record is ava ilable for 
22% of all Canadi ans, and by early 20 II , that proporti on is predicted 
to reach 50%.4 Canada Hea lth lnfoway is an organization charged 
w ith managing the development, and promoting the adopti on of, 
electroni c health record systems in Canada; its goa l is fo r a ll 
Canadians to have an e lectronic hea lth record by the year 20 I 6. 
When we compare ourselves to peers in other nati ons, it is clear that 
we are not keeping pace. In 2006, Canada ranked last among seven 
countries based on the use of hea lth IT by primary care phys ic ians.5 
According to a survey of almost 1500 Canadian physicians, only 
37% use hea lth information technology. The statistic for our hospital 
is more optimistic: approx imately 65% have at least one e-hea lth 
component.4 
What makes this task so daunting? The complex ity of hea lth 
informati on technology lies in the amount of data, the sensiti vity 
(and need for pri vacy) of data, and the hi gh stakes in ensuring the 
accuracy of data . Banking is an industry with similar infom1ati on 
technology needs; according to data fro m 2004, US financial services 
spend 5.4% of their tota l budget on information technology. It is 
therefore no surpri se that we have a long way to go: the average for 
Canadian hea lthcare IT spending was onl y estimated at 1.5-2 .0%6 In 
thi s review arti cle, we will di scuss both the potenti a l benefits and 
challenges to widespread hea lth IT implementati on, a we ll as 
provide recommendations and future directi ons for the fi e ld . 
BENEFITS OF HEALTH IT 
Hea lth in formation technology can deliver a wide range of benefits, 
including system-leve l effic iencies (reduced co t and increased 
productivity), better de li very of care, improved pat ient safety, more 
effective communicati on between providers, and increased access to 
informati on. Whi le we have categorized benefits for the sake of 
discussion in thi s artic le, we recogni ze that these benefits are not 
truly di screte, and are actua lly inter-re lated; for exam ple, when 
prov iders communicate more effective ly, the resulting decrease in 
ambiguity leads to improved patient safety, and ultimately, a cost-
efficiency through do ll ars saved treating an adverse event. 
Enhanced productivity and long-term cost savings: From an 
efficiency perspective, upgrades to healthcare IT can he lp minimize 
wasted time and resources in a c linica l setting. For example, the 
e liminat ion of paper charts increases the amount of physica l space 
that can be used for patient care. Furthermore, computeri zation of 
medi cal records leads to reduced storage and transcription costs. 
After a period of training and adj ustment, e lectronic documentation 
of clinica l encounters would be more rapid than handwritten 
documentation in a paper chart; as such, the amount of time that 
c lini c ians spend on admini strat ive tasks is reduced, freeing up 
va luable time for producti ve c lini cal care. A single e lectronic pati ent 
record can result in smoother hand-offs and tighter connections 
between health providers along the continuum of care, leading to an 
overa ll more efficient care process . Furthermore, hea lth infonnation 
technology can be used to optimize the scheduling of procedures and 
diagnostic tests , reducing overbooki ng and bottlenecks, thus 
all ocating resources more accurate ly.7 
The costs of implementing a hea lth infonnation strategy are 
hi gh. However, evidence suggests that the payoff can be equa ll y 
impress ive. In Canada, for example, the estimated productivity gains 
and savings from a full y implemented electroni c hea lth record are 
estimated at 6 billion 4 There is a growing body of literature that 
presents detailed cost-benefi t analyses of hea lth IT implementation. 
One study8 used US data to demonstrate potential net efficiency and 
safety savings of $8 1 billion each year, after widespread and 
effective e-hea lth adoption. These ga ins in efficiency wi ll ideally lead 
to the transfer of labour to more productive activiti es. The authors 
analyzed other industri es for productivi ty ga ins as a result of 
widespread IT implementati on, and estimated potential gai ns for 
hea lthcare between 1.5 and 4%. 
Another paper9 assessed the va lue of a fully standardi zed and 
interoperable nat ionwide health IT system in the US. Despite the 
hi gh co t associated with this ambiti ous task (estimated ten-year 
ro llout co t of $276 billion), the authors projected a net value of 
$77 .8 billion annua lly after implementation is complete. A third 
study 10 perfom1ed a cost-benefi t ana lys is of an ambulatory care 
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electronic medica l record ystem, and e timated the net benefit for a 
5-year period at $86,400 US per provider. Financial ben~ fit were 
largely realized from aving in drug and radiology expenditures, and 
improvements in reimbur ement (reduced bdlmg error and , 
accordingly, better capture of charges). 
Enhancing the delivery of safe, high-quality patient care: The 
Canadian Adverse Events Study tabulated 70,000 adverse events that 
occur in our ho pitals each yea r, resulting in as many a 23 ,~00 
death . 1 I British Columbia ha implemented a drug mformatwn 
ystem (DI ), wi th great uccess: if the e results are used to make 
projecti ons for all of Canada, we can ex p~ct an electromc DI S to 
reduce inappropriate pre cription by 55 million, and to 1dent1 fy 20 
million drug interactions.4 This positive impact on patient afety can 
al o translate into cost-savi ng . In one tudy, adverse drug event 
were a sociated with an increase in co t of $2,262, primarily due to 
a 1.9-day increase in length of stay. 12 Data cited in another rep~rt7 
sugge t that drug-related event cost the average 200-bed h p1tal 
between 1.6 million and $3 million a year. 
The potential for health in fo nnation technology to reduce er:ors 
i three-fold : by preventing the error upfront, by alertmg clmJCJan 
and allowi ng a more rapid correction of the error, and by reportmg 
and generating feedback about the adver e event.D In a controll ed 
trial eva luati ng the effect of computenzed medJcatJ on orde~ ent~ by 
phy ician , the in e tigator found a 55 percent reduction 111 .s~n ou 
medication errors; a follow-up tudy later eva luated the addJtJon of 
enhanced levels of clinical deci ion support to the electromc 
applicati on, and noted an 83 percent reduction in the overall 
medicati on error rate. 14 A fundamental advantage to electroniC health 
reco rd s is th e elimin ati on of i ue that plague written 
documentation, such as ill eg ible handwriting and incomplete 
medicati on orders. Communi cation breakdowns, most notably dunng 
poor "handoff" between clin ica l team members, are ano.ther 
common ri sk factor for adver e events.13 Hea lth IT can facilitate 
effecti ve communication among providers, particu larl y wi th the u e 
of hand-held wire le s device wi th access to the electronic patient 
chart . 
The capaci ty fo r electronic information systems to facilitate 
effecti ve clinical decision-making is increasi ngly being recogni zed. 
Order entry system can limi t do age or route of admini !rat ion for 
potentially un afe medicati on ; for example, in patient with rena l 
dy function, computerized ca lcul ati ons of safe drug dosage . are 
particularly beneficia l. 13 IT can peci fically improve pati ent 
monitoring. For example, IT y tern can alert clinic ians to 
potentially eriou lab atm rma litie that may otherwi e be 
overlo ked , and promote earlier c rrection : in one trial, this strategy 
decrea ed the duration of dangerou patient cond itions by 29 percent. 
15 In a related approach, technology-enabled remote monitoring of 
inten ive care lead to a reduction in mortali ty of up to 68 percent, and 
a reducti n in average length of stay and associated costs of about 33 
percent. 16 Finall y, hea lth informati on technology can increase linkage 
to clinica l reference and best prac ti ce recommendati ons, all owing 
clinicians to make ev idence- informed decision . 
Increased access to information: Increas ing acce s to informati on 
leads to myriad benefit , at the level of patients, providers, and the 
hea lth y tem alike. Many of these benefits have already been 
rea li zed by prov incial initiati ves. 17 Fir tl y, providers can develop a 
common understanding of pati ent conditions, leading to more 
seamles care for patients. For example, ON Mail is an email erver 
that all w for transfer of pati ent medica l record back to the family 
physician upon di scharge from a hospital. Currentl y, 55,000 Ontari 
hea lthcare wo rker have ONE Mai l accounts. 17 Secondly, hea lth 
informati on technology can also facilitate communicati on and 
co ll abora ti on between prov iders, which i parti cularl y relevant to the 
enhancement of rural hea lthcare deli very. One example, Tele troke, 
is an emergency telemedicine app lication that uses .. two-w.ay 
communication and digital imaging to connect local phys1c~ans w1th 
remote neurologi t located at large urban centers, to ob~m urgent 
di agno is and treatment recommendat.ions about the1r stroke 
t. t Tllus •ar 1200 pati ents have rece1ved urgent care that saved pa Jen s. " ' . . d d d 
I · . 1· 11 TJ1irdly when health informatiOn IS share , re un ancy t 1e11 1 ves. , · · b fi · 1 
and the need for duplicate testing are decreased; th1s IS ene JCJa . to 
patient , who wi ll no longer have to undergo. unnecessary repet1t1on 
of te ts, and a a ystem-wide co t-effic1ency sm~e additiOnal 
expen ive te ts can be avoided. A local s~ccess story 111 th1 s arena, 
the South Western Ontario Digital lmagmg . etwork (SWOD~) 
pro ides regional hea lthcare providers electroniC ac~ess to a pat1en~ 7s medical imaging result , when taken at any hosp1 tal 111 the network. 
Beyond the e to at ucce tories, there a.re other intriguing 
potential outcome of increased access to health mform~t10n . In o~e 
cena rio, where patients are to rece1ve access to the1r electrom.c 
hea lth record, they could use this informat1on to manage the1r 
chronic condition on a day-to-day ba i , identi fy ri sk facto r , and for 
self-care . One important benefit that can be felt on both a system-
and patient-level i reduced wait times. The u e .of hea lt.h IT to ~a­
ord inate and manage wait lists, and to make \ a1t time mformatwn 
acces ible to the public in real time, i well document~d. In the UK, 
for example, their national health sy tem reports wa1t t1mes .data that 
i le than one month old. 18 uch, patient can make an mforme.d 
decision about where to go for care. A related benefit of hea lth IT 1 
the wea lth of data that are made readily avai lable; this is u efu l both 
for reporting of health tatu to the provi ncia l government, and for 
reporting of performance indicator (e.g. length of stay and mortality 
rates) to increa e h pita! accountab ili ty. 
BARRJERS TO UCCESS 
One reviev 3 provided a uccinct classificati on of four types of 
barrier to the implementation of health information technology. 
ituational barrier include time and financial concerns; cognitive 
and/or phy ica l barrier include phy ical di sabi litie and in ufficient 
computer kill ; liabi lit y barriers include co ncerns about 
confidentia lity; and kno\ ledge and att itudinal barrier include 
apprehen ion about change or lack of awarenes of potential benefits. 
With re pect to financial concerns, it is no urpri se that 
wide pread hea lth information technology implementation come 
with a hefty pric tag. The co t of implementation include oftware 
and hardware, training, work Oow proce s redesign, hi torica l paper 
chart ab tracting, and ongoing maintenance and upport. There are 
al o indirect co t as a re ult of the transition from a paper to 
electronic y tem, uch a the temporary decrea e in provider 
producti ity after implementation, a they adjust to a new y tern . IO 
The creation of an electronic hea lth record for all anadian is 
projected to co t 10 billion.4 In Ontario alone, thee timated total 
cost of a three-year e-hea lth trategy- which focu e on diabetes 
management, medication , and wa it times- is over 2 billion. 19 
Compounding thi s high co t is the fact that the pre umed financial 
payoff is delayed: one review including 82 studies with co t-benefit 
analyse bowed the time to break-even on hea lth IT inve tment wa 
between 3 and 13 year .3 In some cases, the fina ncial payoff may 
also be uncertain- particularl y for physicians operating in a mall 
group or olo practice, where the return on investment i le 
ub tantial, and there i no forn1a l organi zati onal upport for training 
and re tructuring.20 Moreover, the ta k of performing a co t-benefit 
analy i can it elf po e diffi culti e , given the chall enge of a igning 
do ll ar va lues to producti vity ga in or improvement in pati ent ca re. 
With re pect to attitudinal baJTier , Poon et aJ21 noted the 
perception that hea lth informati on technology could have a negati e 
impact on clinica l proce se . This peaks to the fact that technology 
cannot be applied to a clinica l area without careful workO w 
analy es; where nece sa ry, updated protocol hould be implemented 
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that are in sync w ith the new technology. The authors21 a lso noted 
that product and vendor immaturi ty was a barri er; many current 
software offerings were not compatibl e w ith hospita l needs, and 
various modifi cati ons were necessary to acco mmodate th e hospita l's 
current workflow. 
Hersh22 reported that system and data interoperability was a 
major concern , noting the " information s ilos" pervas ive in manag ing 
healthcare data. Further to thi s, sma ller, pilot proj ects are o ften more 
affordable, and thus, des irable from a management perspecti ve; this 
becomes a problem when a hea lth system has multipl e incompatibl e 
e lectroni c medi cal records, and an expens ive standardi za ti on process 
must be undertaken. Hersh22 al o identified the need for a workforce 
tra ined suffi c iently in c linica l in formati cs to ro ll -out such a complex 
implementati on process. A re lated cogniti ve barri er is the lack of IT 
knowledge and tra ining in hea lth profes iona l educati on; thi s can 
certa inly impede front-line c lini cian ' acceptance of technologica l 
trends in their workpl ace. 
CONCLUSIONS 
Recommendations: An e lectroni c hea lth informati on system has a 
large impact on the day-to-day work of both c lini c ians and hospita l 
admini strators. As such, there i a c lear need to engage, and ensure 
buy-in from, these stakeholders earl y in the dec ision process7 Health 
profess iona ls in particul ar should be con ulted in order to e lect and 
build an e lectroni c system that i compatible with clinica l needs and 
patient fl ow. One approach i to des ignate key phys ic ians as 
"champions" of the process, who can then help moti vate other 
clinicians and admini strators, and promote acceptance and adoption 
of the IT system 7 Often times, there is res istance among front-line 
staff when a change is seen as coming from admini strato rs who are 
not familiar with c linica l processes; if the process is supported by a 
respected c linical co ll eague, however, other c lini cians tend to be less 
wary. It is also important not to underestimate the sca le o f such an 
implementation process . The process may inc lude modificati ons to 
the software architecture and the establi shment of new standards of 
care or changed medica l practi ces. Change management itse lf 
requires resources and time; for example, in one Canadian hospital 
system, approx imate ly 30 percent of the tota l proj ect budget was 
allocated to thi s stage. 7 Another approach is to implement an 
infonnation technology ystem in a succes ion of phased pilots; the 
project team can identi fy lessons learned and apply them to 
subsequent ro llouts. If pilots are successful , other clinical areas w ill 
be eager to undergo the same change. Increas ing education and 
awareness about the benefits of hea lth information technology w ill 
boost acceptance of change on the part of the general publi c and 
health providers alike. Data eluc idating these benefits are required 
for such endeavours; c lini ca l settings where IT systems have been 
implemented should be encouraged to co llect, analyze and publi sh 
data on the results. Finall y, having di verse applicati ons and software 
platforms increases complex ity, ra ises costs, and length ens 
implementation timeframes. 7 As such, at a time of rapid adoption of 
health IT, it is crucia l to implement a simple, unifi ed system. It will 
be important to maintain an integrated e-H ea lth Ontari o strategy to 
facilitate this . 
The path ahead: Health information technology has created endless 
opportunities and has enormous potential to transform the de livery of 
healthcare. The possibilities even surpass the biomedical model: an 
e lectronic health record has the capac ity to link c linica l data to 
indicators of soc ioeconomi c statu s, a ll owin g a rema rkabl e 
understanding of the impact of soc ia l determinants of hea lth . 
However, this changing landscape has also challenged us with 
important questions. 18 Who will have access to thi s wea lth of 
infonnation? Will patients be able to view the ir own e lectronic 
record? If data are anonymi zed, are they then ethica l for government 
reporting and public use? Will health information technology be used 
to increase transparency, by provid ing outcomes data to the genera l 
public? Will c lini cians fee l comfortable operating in such a system, 
where the ir post-operati ve morta lity rate is wide ly publi shed? And 
perhaps most importantly, will the myri ad stakeholders em brace the 
opportuni ty to co ll aborate and use infonnati on fo r the advancement 
of hea lth? We look forwa rd to leamin g the answers to such questi ons, 
and hope that innovations in hea lth in fo rm ati on technology w ill be 
embraced acros Canada. 
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Using texts for safe sex: technology in 
adolescent sexual health 
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Faculty Reviewer : Dr. Lois Champion . Critical Care and Anesthesia 
R i ky sexual behaviour among adole cents is a ignifi cant cau e of infection and morbidity, as well as un wa nted pregnancy. In the United State , 25% of females between 
14-1 9 have acquired a ex uall y tran mitted infection (STI) and 
adolescents between I 0-24 account for more than 20,000 new cases 
of HIV/AIDS annually.1 While many STI are eas ily treatable, they 
can also lead to pelvic inflammatory di sease, chronic pain , or 
cervica l cancer and infertility.2 As we ll , there are over 745,000 
teenage pregnancies in the US every year.1 Therefore, promoting 
se ual hea lth through youth - pec ifi c interventions is an important 
topic of research and concern . 
In the past, sexual hea lth promotion interventions (S HPI ) have 
been provided through chool programs and sexual hea lth clinics. 
Through thi s medium, informati on is typica ll y given face-to-face by 
hea lth care workers and is complemented by print materi als. While 
these trategies have hown moderate succe , they are limited by 
cost, time, and access ibili ty.3 Face-to-face HPI have not been hown 
to ub tant ia ll y impact Tl in fecti on rate , unplanned pregnancy 
rates, or number of sexual partners, although they have been shown 
to increase knowledge about sexual hea lth and condom u e.3 The 
introduction of new technology all ows for a less expensive and more 
effi cient way of promoting sexual hea lth to the largest number of 
people. The most successful technology-ba ed SHPI to date have 
involved either internet-based interventions or tex t-messaging-based 
interventions. Since 93% of U adolescents have a computer at home 
and 85% of 14- 18 year olds own a cell phone,4 these media prov ide 
exce llent access to the adolescent populati on. Technology-ba ed 
SHPI have not onl y been shown to reduce ri sky ex ual behav iour and 
increase knowledge of sex t.ml hea lth ,3•5•6 but can reduce co t and 
time spent by hea lthcare workers by shift ing the burden to more 
automated technologies 7 
Sex ual hea lth promoti on con i ts of prov iding indi viduals with 
the too ls to make informed dec i ions about their ex ual we ll -be ing. 3 
The overall goa l is to improve the sex ual hea lth of a populati on 
through commun ity-based interventions. In order to do so, however, 
one mu t first identi fy th e reason that ind iv iduals, espec iall y 
adolescents, engage in ri sky sexual behavio ur. Recent research into 
adolescent moti vation fo und that the fo ur main factors that contri bute 
to these behaviours are: low perceptions of ri sk, lack of confidence, 
the influence of social norms, and inaccurate knowledge.s Most 
interventions ai med at adolescents focus on thi s last factor by 
providing information on Tl and contraception; however the e 
strategies have shown onl y marginal ucces .2 Sex ual hea lth 
promoti on interventions must not onl y focus on biologica l outcomes, 
such as STI incidence rates or teen pregnancy, but on behav ioural 
and emoti onal outcomes - increased self-e ffi cacy, moti va ti on to 
change, and confident dec ision-making. 
Technology-ba ed strategies can incorporate thi research by 
providing populati on- peci fi e interventions that touch on multiple 
a pects of exual hea lth . Studies have shown that interventions are 
more effective when they are ba ed on behavioural theori es and 
address the soc ial and p ychologica l cau e of risky sexual activity.5•8 
lntern et-ba ed and text-me aging-ba ed interventions have the 
abili ty to promote behavioura l change by u ing the convenience, 
peed, and ubiq uity of these technologies to access at-ri sk 
adolescents . 
lnternet-ba ed HPI are promi ing because they a llow for 
anonymou , repeatable, con enient, and inexpensive interventions 
that can reach populati ons that are more res istant to mainstream 
medica l ca re3 Almo t 50% of youth urveyed have already used the 
In ternet to search fo r sexual hea lth in fo rmati on.5 A recent Cochrane 
Review meta-analysis of interacti ve, computer-ba ed HPJ found 
igni fica nt effect n both behavioural measurements, uch a 
condom use, and psychologica l mea urement , such a confidence 
and elf-efficacy3. Fifteen RCT \ ith 39 17 part ic ipant were 
reviewed. In keeping wi th pre ious fi nding on the importance of 
moti vation and dec i ion-mak ing in behaviour modification5, the 
review focused only on interventions that required user contribution 
and provi ded persona lized feedback. The mo t ucce ful 
intervention were tai lored to an individual's leve l of knowledge and 
invol ed role-playing or ituational exerci es.3·4.8.Q.JOStudie that 
foc u ed specificall y on adole cents were also more ucce ful if they 
a oided negati ve me ages and scare tacti cs, and ta rgeted peci fi e 
behaviour . Many of the e intervention exempli fy the principles of 
hea lth promoti on becau e they not onl y educate, but al o prov ide 
u ers with the confi dence and motivati on required to make safe 
dec i ion in the future.1 Other web ites prov ide user with 
anonymous and acce ib le way of improv ing sexual hea lth ia mail-
in Tl te ts or onli ne contact-trac ing after Tl diagno i .1 
Us ing text messag ing to promote adolescent sexual hea lth has 
many adva ntages . Tex t mes ages are fast, conveni ent , and 
inexpen ive; they can be sent to multiple individuals at the ame 
tim ; they. are very popular among adole cents, and text mes aging 
rate are unil ar bet~een socioeconomic groups.6 Tex t me aging has 
been Incorporated 1nto exual hea lth ca re in numerous ways, with 
encouraging results: Sexual hea lth clinics in the UK have begun 
prov1d111g results of Tl tests via tex t mes age if des ired - 70% of 
adolescents preferred thi to booking a follow-up appointment.? The 
UK ha . a l ~o . begun a text mes aging "Grab a Condom" campaign, 
where mdJ v1dual can request condoms and have them home-
deli vered6 Other clinic have begun providing daily text mes age 
remmders to pat1 ent about taking oral contraceptives, and have seen 
a ignifi cant improvement in reported compliance6 The most 
prom1 mg intervention, implemented in an Franci co aiiO\ 
indi viduals to text " XINFO" from any mobile phone and r~ce i e 
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infom1ation about sexual hea lth , relati onships, and nearby clinics . In 
the fir t 6 month , SEXINFO rece ived more than 4500 tex t mes ages 
and those who remembered seeing adverti sements for the ervice 
were ignifi cantl y more likely to be concerned about STI .11 Wh ile 
not yet widely used, tex t messag ing shows promise a an effecti ve 
SHPI that can be u ed to target adole cents directly. 
The use of technology-based HPI is relatively new, although 
their effectiveness has been demonstrated in numerous tudies . 
However, there are till concem that these strategies may be aving 
time and money at the expense o f accuracy and hoi isti c care. A recent 
study of 177 sexual health website showed that 17% contained one 
or more medica l errors, and the number of errors was correlated with 
the complexity of the topic at hand. 12 Sex ual hea lth web ites foc u 
strongly on STis and contraception, but often only contain a cursory 
treatment of how to express sexuality, body image, and the po iti ve 
aspects of sex. 13 A recent study of 30 "Positi ve Youth Development" 
interventions- tho e that focused on empowerment of di adva ntaged 
youth - howed that all ucce sful in tervention invo lved a 
supporti ve environment containing pa rents, teachers, or hea lth ca re 
providers. 1 Can technology-based interve ntions provide thi s ame 
level of support and intimacy? ea rl y half of teenager cited their 
parents a the people with the most influence in their sex ual dec ision-
making, yet very few of the intemet- or text mes aging-based 
interventions encourage parental in vo lvement. 5 Moreover, prov idi ng 
STI results via text messaging led to a decrease in foll ow-up visits, 
which wa hail ed a a succes by the UK sex ual hea lth clin ics 
invo lved .14 However, if the e in terventi ons lead to fewe r 
conversation between adole cent and their hea lth care prov iders, is 
this reall y omething to ce lebrate? 
Media and communication technolog ies, like Internet and text 
messaging, have the potential to be used as fa r-reaching and cost-
effecti ve method of promoting sexual health among adolescents. 
Initial studie demonstrate that the e intervention can successfu lly 
provide knowledge, motivate people to change behaviour, and 
encourage adolescents to seek medica l ca re when necessary. 
However, few studies have measured their effect on long-term 
outcomes, uch as STI in fection or pregnancy rates . As we ll, some 
concem remains that technology-based SHPI cannot full y address the 
emoti onal needs of adolescent in the same way a face-to-face 
conversations with a hea lthcare provider. Neve11heless, it is thought 
that reaching adolescents "on their own turf' , by using media they 
are comfortable and fa miliar wi th , may encourage them to seek care 
when nece ary and fee l more motivated to practice safe sexual 
practices. 
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PACS, SRR and the future of radiology 
Ashley Kim (Meds 2013}, Emma Farley (Meds 2013) 
Faculty Reviewer: Dr. Richard Rankin (Department of Medical Imaging) 
T he complex organi zation of the Canad ian health care system has led to fragmen ted care, and cha ll enges in interdi sci pli nary communicati on. Adva nce in techn ology, however, are 
rapidl y enh anc ing th e potenti a l fo r multipl e di sci plines to 
communi cate and integrate infonnation. Many of these advances 
have been fostered under the leadership and influence of radi ology. 
Innovati on i described as hav ing two components: the 
development of new technologies, and their adoption into c lin ica l 
pract ice1. Both are req uired fo r a rea l impact in med icine. Beginning 
with Roentgen 's discovery of x- ray , innovat ion in new imaging 
techniques like ultrasound, CT and MRI ha propelled radio logy to 
the fo refront of cutti ng edge med ica l science. Furthennore, leaders in 
radiology have pioneered efficient communication and electroni c 
storage strategies to more effi ciently adopt these imaging modalities 
into c linica l practice, accessibl e to a larger group of caregiver 2 
Pi cture Archi ving and Communication System (PACS) is ju t one 
example that has now been implemented in hospita ls acros the 
country and throughout the world . 
The fi eld of radiology has been exemplary in using innovati on 
to fac ilitate multidi sc iplinary care. O ften, however, the e innova ti ons 
are adopted or complete ly taken over by other pecialti es resulting in 
" turf wars", whi ch create animos ity, hindering co ll aborati on on a 
fundamenta l level. In additi on, it is poss ible that ince technology ha 
reduced face- to-face time in non-medi ca l rea lms (e.g. Facebook, 
online chat, blogs), it could a lso negati vely impact communicati on in 
medic ine. Thi arti c le argues, however, that an increase in 
compute ri zed communi ca ti on is a pos iti ve deve lopment fo r 
inte rdi sc iplina ry co ll a bo rati o n owi ng to th e nature o f th e 
technologies used. Thi s arti c le will a lso outline so me exa mples of 
current techno logy that have co me to ymbo li ze the concept o f 
computerized clini ca l integrati on. 
Despi te literature that bemoa ns the decrea ed c lini ca l pre ence 
of radi o logists caused by technology, its adva ntage to pati ent care 
ca nnot be ignored. A radi ologist stated, " the say ing 1empora 
mulantur is as true today as it was in the day o f the Roman : time 
change, and we must change with them"3. Radio logists have been 
pi vota l in deve loping these modern technologies and now must adapt 
to best reap the ir rewa rds. 
PICTURE ARCHIVING AN D COMMUN ICATION SYSTEM 
PACS re fers to the e lectroni c storage of multimoda l data 
inc ludin g imag ing studi es, repo rts and pati ent identifi ca ti on 
in fo rmat ion. PACS replaces hard copy data ( films and paper records) 
and all ows the integration of imaging with oth er systems such a the 
Electroni c Medi ca l Record (EMR). There are severa l storage format 
fo r PACS, whi ch a ll generall y inc lude images (whi ch can be T, 
MRI, US, PET, endoscopy, mammograph y, oph thalmology, etc), a 
secure network, multip le workstati on (whi ch can ex ist at mu lti ple 
ho pita ! si te ), and patient archives . PACS fac ilitates remote access, 
and is u ed by radio logists to perfonn te leradio logy, or off- ite image 
in terpretation. Integrated into PAC is a workfl ow management 
system, which a llows fo r an efficient a ynchronou communicati on 
ys tem4 . In other words, once the image is acquired , pre liminary 
comments can be made by the technic ian or referring phys ic ian. In 
addi tion, if a diagnos is is made immedi ately and acted upon, say in 
the ED, thi is recorded and can be later re-eva luated by the 
radi ologi t who can either agree or d isagree wi th the ori gina l 
impression. This a llow for a ystem > here discrepanc ies can be 
recorded and later studi ed fo r particular patterns of error. 
In the tudy by Mate e / a/., an add iti ona l communication tool 
was implemented a longs ide PACS, ca ll ed Co ll aborative N otificati on 
System (C ), whi ch was used in the sett ing of urgent or emergent 
radi o logy4. C con i ts of a pager notifi cati on system between the 
radio logist and referri ng physic ian, and allows for image to be read 
immediate ly, and the d iagnosis paged to the referring phy ic ian w ho 
can then acknowledge its receipt. The system was shown to improve 
documentation, and provided an exact record of the communicati on, 
whi ch would not be ava il able wi th per on-to-person communicati on. 
CN is j u t one way in which PAC has been shown to fac ilitate 
radio logi t wo rkfl ow. 
Additiona l bene fits of PACS include an increase in 1mage 
ava ilability as well a a decrea e in time pent travelling to the 
radi ology department5 Another report demonstrated that PACS 
enh anced communica ti on between radi o log i ts and re fe rring 
ph y icia n by decrea ing e rro rs re lated to inco rrect pati ent 
identifi cati on, and increased the e ffi c iency of meetings by pro iding 
readily ava ilable image and report 6. More manageable workflow 
and increa ed effi c iency of inter-phys ician communication are 
undeni able here. Unfortunate ly fo r radi ologists, however, more 
acces ibl e image data may lead to an increase in the number of non-
radio logist physic ian who interpret radi o logica l studies. 
SPEECH RECOGNITION REPORTI NG 
Speech Recogniti on Reporting ( RR) has been wide ly ava ilable in 
hea lth ca re worldwide fo r the Ia t 15 or so year , but recentl y 
Improvements have been made such that the vo ice recognition 
sy.stems are more ophisti cated, requiring less voice-tra ining time 
w1t~ 1ncrea ed word-recognition accuracy. Radi o logi t have been a 
maJor con umer o f SR~ as it ha been shown to significantly reduce 
the .tune between examJ.nation and report fin a li zation 7·s. Tradi ti ona lly, 
radiOl ogists wo uld di ctate report , whi ch were recorded and 
t~an scribed at a .later time: and fin a ll y veri tied by the radio logi t and 
s igned off for mc lus1on m the patient chart or EMR. With RR 
vo ice i converted directly to tex t a fter the RR oftware ha bee~ 
trained to the parti cul ar user 's voice. The report then appears 
unm ed1ate ly 111 the EMR and as part of the hospital 's PA S . The use 
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of SRR along ide PACS ha been hown to ignificantl y reduce 
report completi on time a we ll a igni ficant ly inc rea e the number 
of reports which are avai lable with in 24 hourss. 
Another benefit of RR, hown by Bhan et a/., is the decrease in 
overall hospital operati ng costs8 The ame report, however, 
publi hed data bowi ng that RR actuall y increased the amount of 
time taken to produce indi vidual reports, and was prone to 
inaccurac ies in certai n ettings, for exampl e, when used by 
practitioner for whom Engli sh was a econd language. Speech 
Recognition Reporting wa hown to have no effect on the overall 
number of report produced. De pile some of it shortcomings, RR 
has recently hO\ n a t improvement and wi ll undoubtedly cont inue 
to do so. It has become a main tay for many radio logi ts and other 
specialties alike and ha the unique ability to be combined with 
ystem such a P to provide a more complete compo ite of 
patient data, benefitting all member of the interdi ciplinary team. 
THE FUTURE OF RADIOLOGY 
ince many technologie have improved the efficiency and 
accuracy of radiological reporting, there has been a parall el increase 
in the adoption of radio logical technique by other spec ial ti e . This i 
known to many a radio logy "turf war ". The most prominent 
example over the pa t 40 year are in va cular urgery and coronary 
angiography. One author specu lated that the rea on for the total 
ces ation of radiologi t perfom1ing these procedure was their lack 
of specific knowledge in the clinica l aspects of coronary artery 
di ea e (e peciall y electrocardiology and ca rdio pharmacology) a 
well as the ability of cardiologist to se lf- re fer9 Palma notes that 
since radiologists are not trained in the catheter lab and do not 
conduct research in coronary disease, they are less adept to perform 
coronary angiography. Thus, radiologi t have largely abandoned thi 
practice. One study showed that the tota l number of intravascular 
procedure perfom1ed by radiologist fell from 63 .6% to 49%, whi le 
those perfom1ed by ca rdiologi ts ro e from 25% to 36% from 1997 
to 2002 10. Radiologists, however, have longer and more high ly 
specialized education that include in-depth radiati on sa fety training, 
familiarity with all imaging modalitie , and ability to detect 
incidental findings " , which suggests that they are better suited for 
these procedures. The previous ly mentioned phenomenon of se lf-
referral has also been explored and shown to lead to an increas ing 
and unnecessary utilizati on of radiologica l se rvices by non-
radiologists1 2. 
The high le el of technical ability inherent in radio logy ha led 
to a real or perceived weakening of the clinical re lationship between 
radiologist and pati ent. Therefore, there ha been a recent pu h 
towards olution termed "clinica li sation", wh ich reinforce the 
clinical role of radiologists and their technologies3·9· 13 . Clinica li ation 
also seeks to help radiologi ts better communicate wi th other 
discip lines by recommendi ng training for radiology resident in 
spec ific organ patho logies, and upports the phys ician-pati ent 
re lationsh ip by encouraging radiologists to maintain contact with the 
patient in all phases of treatment13. Additionall y, centers in the 
Un ited States ha ve explored the po sibi li ty of using online images to 
increase patient access . Thi wa found to increase pati ent 
sati sfaction , and support the relationship with and identificati on of 
the radiologist a a profe sional responsib le for diagnosis and 
treatment14. 
CONCLUSION: WILL TECHNOLOGY HELP OR HINDER 
RADIOLOGISTS? 
Innovation in radio logy is influencing many aspects of medicine 
that include comm unication, management, diagnost ics and therapy. 
The future of radiology undoubtedly in vo lve further development of 
PACS and SRR systems and their becoming so widespread that 
transmission of images and report to patient mart cards, nati onally 
( 
or intemati onall y i po ible .15 Telemedicine and vidoecon ferencing 
wi ll also enhance large- ca le communication. The next few decade 
wi ll ee further advances in nanotechnology, molecular imaging, and 
new forms of percutaneous treatment. Radiologists who have 
experti e in electronics and informati c , a foundation of specialized 
clinica l pathology and exce ll ent bed ide man ner will help shape the 
way innovation i implemented in day-to-day med icine. 
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Lab-on-a-chip technology: the future of point-
of-care diagnostic ability 
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0 ne of the greate t cha ll enges in modem medic ine is the ability to provide accurate diagnosti c laboratory te t in developing countries and in remote areas where conventi ona l 
analytica l laboratorie are lacking. Imagine running a cli ni c in a 
remote area o f rural Africa, the Canadian arctic, on a military fi e ld 
ba e or even in a small rural community in Ontario and hav ing the 
abili ty to provide accurate, rapid, po int-of-care di agnostic lab tests 
wi thout the infrastructure of a full ana lyt ica l laboratory ' There 's no 
need for a cumbersome or ex pens ive mass spectromete r, a 
spectrophotometer, a fl ow cytometer or even a centrifuge beca use the 
application of mi cro fluidi cs eng ineering to medi ca l diagno ti cs ha 
enabled laboratory tests to be performed on a ma ll microchip the 
size of a credit card that you can carry around in your pocket and 
may only require the use of a battery as a power source for analysis! 
As futuri sti c as this idea seems, the appli cation of mi crofluidi cs 
engineering to the deve lopment of medical diagnostic te ts is very 
much a rea li ty. 
Microfluidic s eng inee ring is a multidi c ip linary fi e ld of 
eng ineering where the intersection of the fie ld of phys ics, chemistry, 
eng ineering and biotechnology have come together to deve lop chips 
on which the ana lys is of fluids can occur on a microsca le leve l. A 
parti cular ly interesting application of micro fluidi cs eng ineering 
technology is the deve lopment of a lab-on-a-chip ; a pl atform on 
whi ch one or more laboratory te ts are integrated onto a sma ll chip a 
few square centimetres in ize that uses a very sma ll volume of fluid 
for anal y is. Severa l mi cro! iters of a vari ety of biologica l fluid 
in cluding blood, cerebro pinal fluid , urine, feces or sa li va ca n be 
added to the lab-on-a-chip fo r analysis. 1 The e chips utilize a wide 
vari ety of techniques for analysis. The most succes fu l lab-on-a-chip 
applications integrate all aspects of sample preparati on, ample 
separati on, signa l amplifi ca ti on and signa l detecti on on a s ing le chip . 
1 These chips ca n be ea ily adapted for use in remote regions since 
pecialized laboratory personnel are not needed for ana ly i - yo u 
simply need to appl y the sample to the chip and the tec hno logy take 
care o f the rest. In additi on to the ir sma ll ize and portability , the 
appli cati ons of lab-on-a-chip platforms have a wide vari ety of 
advantages to the fi e ld of medi ci ne and are li sted in Box I (adapted 
from references ( 1-3)) . A vari ety of molecul ar biology, immunology 
and biochemi ca l techniques ha ve been adapted for use on lab-on-a-
chip platforms inc luding protein assays, nuc leic acid as ays, cell 
sorting, and biological analyte detecti on. '.4 Since lab-on-a-chip 
technology has a wide variety of applications in medicine we will 
now focus on two areas o f interest where we fee l the technology will 
be rapidl y appli ed; the detecti on of infecti ous mi croorgani m from 
biological amples i.S·6 and the microsca le detecti on of bio logica l 
ana lytes 7 
Arguably, one of th e most important and exciting app lica tions of 
these devices is in the ea rly and accurate diagnosis of infecti ous 
di sease in the developing world .1.35 ·6 The ability to rapidl y detect 
an infecti on, a ess an infected patient 's health status and the 
appli cati on of this techno logy to epidemio logica l studies in the field 
are inva luable. In order to be a useful tool in the developing world 
severa l de ign challenge need to be overcome; the reagents and the 
chip itself need to be stable at a wi de variety of temperatures since 
refrigeration of the component may not a lways be feasible in the 
de elop ing world , the cost of the chips needs to be low and the chips 
need to have a small power ou rce for operat ion ince re liable 
electrica l infrastructure is not found in a ll parts of the world. ' ·3 
Re earch and deve lopment work is being undertaken to adapt lab-on-
a-ch ip technology for the detection of many microorganisms from 
biological amples including; HJV (reviewed in (8)), ma laria 
(rev iewed in (9-1 0)), tubercu lo i 11 · 11 , diarrheal di seases6, pertussis 13, 
and dengue fever. 14 One excit ing lab-on-a-chip application for the 
detection of enteric infection i the Disposable Enterics Card (DEC) 
which i able to detect the presence of Campylobacter jejuni, 
Escherichia coli 0 157: H7, Shigella dy enferiae, Shiga Toxin-
producing Escherichia coli ( TEC) and Salmonella from a amp le of 
feces a ll on one microchip.6 The DEC lab-on-a-chip technology 
combines evera l laboratory assays to detect the bacteri a (see Figure 
I and Figure 2 for a chematic of the chip). Brie fl y, a ample of feces 
i appli ed to the chip and bacteria from the sample are captured on 
the chip by using pecific antibodie to each bacteria of interest. 
The e antibodie are located in severa l different areas of the chip. 
The bacteria are ubseq uentl y ly ed u ing buffer and the bacterial 
DNA i captured on a silica resin co nta ined within the chip. The 
purifi ed bacteria l ON is ubsequently amplifi ed u ing a tandard 
molecu lar biology technique ca ll ed the po lymera e chain reaction 
(PCR) with ON primers spec ifi c for a gene in each bacteria l pec ies 
of mterest. The end of each primer ha been de igned to contain a 
flu ore cent molecul e. After the amplification of the bacterial 0 A 
using P R, flu ore cent molecule are now found at the ends of each 
Figu re I. A Schemati c Diagram of the Disposable Enteric ard 
(DEC) lab-on-a-chip Techno logy. 
24 UWOMJ I 80 :1 I Spring 2011 
amplified molecul e of bacteri a l DNA . The next step in the process is 
to detect the amplified bacterial DNA . To do thi , a laser li ght is 
directed at the ample. The fluorophore em its fluorescent li ght 
which can be detected if the sample is positive for the bacteria . 
Unfortunate ly, the DEC testing till require the use of a small 
machine for the PCR reacti on and PC R product detecti on whi ch 
limits its abi lity to adapt to fi e ld conditi ons. This technology would 
be useful in a small analytica l laboratory or c linic but it u efu lne 
would be limited under fi e ld conditi on . 
A second application of technology to lab-on-a-chip capabi li ty is 
the detection of analytes uch as e lectrolytes fro m a small sample of 
blood. The iSTAT, a device manufactured by Abbott Diagnostics, 
has the capab ili ty of rapidly analyzing analytes in a few drops of 
blood.7 The developers of the iSTAT have miniaturi zed e lectrodes by 
depo iting electrode arrays onto sili con cartridges to create a 
biosensor. A few drops of blood depos ited into a sample chamber are 
able to enter the caitridge by capi llary act ion. Once the sample is in 
the cartridge it can be treated with chemica l reagent prior to 
analysis. At the analyt ica l stage the cartridge is inserted into a 
handheld e lectromechanica l read-out device that prov ide a power 
source and controls the temperature of the chip. The electrode arrays 
depos ited on the s ilicon membrane can then be used to measure the 
concentration of various blood e lectrolytes, gases, and other analytes 
using potentiometry (measuring the e lectri c potential), 
Box 1: Advantages oflab-on-a-chip technology 
• Small size (credit card or smaller), portability 
• small sample volumes, less invasive 
• rapid analysis, short processing times 
• low cost 
• no need for highly trained laboratory technicians 
to perform the test 
• may run using a battery for power (no need for 
electrica l infrastructure) 
• reduced reagent consumption due to small volumes 
• high reproducibility 
• reduced exposure to hazardous materials or 
infectious agents due to small volumes 
• minimal risk of sample contamination 
• convenient disposal 
• elimination of human error (you add the sample 
to the chip and the chip takes care of the rest) 
Adapted from references (1-3} . 
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Figure 2. Biochemical steps of the anal ysis in the chip. (A) Feces sample is applied to the chip and enters the sample well. Various types 
of bacteria in the sample are represented by different ova ls . Different surface prote ins on each type of bacteria are denoted by rectangles 
and tri angles. (B) Antibodies speci fie to surface prote ins on the bacteria of inte rest capture the bacteri a in the chip. This example shows 
black coloured bacteria captured in the upper chamber and grey coloured bacte ria in the lower chamber. Bacteria whose surface prote ins 
are not bound by the antibodies are washed away. (C) Captured bacteri al ce ll s are lysed in buffe r and bacterial DNA is purified on sili ca 
resin . (D) Purified bacteria l DNA is e luted from the res in and enter the PC R amplifi cati on chamber. (E) A bacteria l gene of interest is 
amp lifi ed using a standard molecul ar biology technique ca lled PCR. Small DNA mo lecules (primers) specifi c for the gene of interest are 
found in thi s chamber. Primers are denoted as arrows in the di agram and are linked to a fluoroph ore (a flu orescent molecule) denoted by a 
star. (F) The gene of interest is amp li fi ed exponentia ll y (there are many copies) and now conta ins flu orophores on each end. (G) Amp li tied 
bacterial DNA fluoresces when laser li ght is shone on the sample giving a readout, thus, leading to the di agnosis of the infecti on. 
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amperometry (measuring the fl ow of an electri ca l current) or 
conductimetry (mea uring the conductance) of the sample.7 These 
values are then di splayed on a screen. Different chips are u ed for 
different analytica l application and each chip is dispo ed of after 
one use. All the chips use the same handheld electromechanical 
read-out device. 
We have only focused on two application of lab-on-a-chip 
technology; however, there are numerous u e for this technology 
and many approaches to the miniaturi zation of biochemica l, 
molecular biology and chemical a ays for u e on microchip . The 
miniaturization of medical technologie may very well revolutionize 
the deli very of medical care in the near future. I your pocket ready 
for the lab-on-a-chip? 
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An Interview with Dr. Ting-Yim Lee, PhD 
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Physicians are often limited by techno logy in their pursuit of patient wellbeing. Take for example a pati ent suffering from stroke among a myri ad of other diseases. Having the capac ity 
to measure blood flow to various organs and to specifi c regions 
within those organs - vita l for proper bodi ly fun ctions - can have 
prodigious implications on dec iding which treatment plan to follow. 
Fortunately, measuring functi onal bodi ly processes with respect to 
hemodynamics has been a specia lty of Dr. Ting-Yim Lee. Dr. Lee 's 
research on blood fl ow has contributed substantiall y in 
allowing physicians to apprec iate a more comprehensive 
picture of some of the most severe di seases. But the journey 
so ftware, whi ch can measure fu nctional aspects of blood fl ow to the 
bra in (see Fi g ures I ,2) , in c ludin g ri sk fo r he m o rrh ag ic 
transformati on. Taking into acco unt ischemic brain changes after a 
stroke can lead to more inclusive treatment criteria for thrombolysis. 
As such, thi s could lead to reduced di sabili ty fo ll owing stroke, 
therefore poss ibly miti gating other severe treatment compli cations. 
there has not been easy. 
Winston Churchill once 
sa id, "Continuous effort is 
the key to unlocking our 
potenti a l. " Thi quotati on 
best exemplifi es the dri ving 
fo rce behind Dr. Ting-Yim 
Lee's research endeavours. 
Having grown up in Hong 
Kong, Dr. Lee travell ed to 
Lo nd o n U ni ve r s i ty in 
England to pursue graduate 
degrees in Radiati on Physics 
i n th e D e p a rtm e n t of 
N uc lea r M e di c in e . To 
further hi s research interests, 
he immigrated to Canada in 1983 . Dr. Lee exemplifi es the 
qualiti es of a committed, ambitious scientist who manages to 
go above and beyond the typ ica l protoco l. He is hard working, 
humble and extremely knowledgeable in hi s research deri ving 
functional and physiological info rmati on from contrast CT 
images. The Uni versity of Western Onta ri o has been fo rtunate 
enough to have him fo r well over two decades now. Whil e at 
Western, Dr. Lee quickly emerged as a leader by deve loping a 
renowned fun ctional CT Imaging program. His aspirati ons are 
to study fun cti onal processes in the human body us ing CT 
imaging, specifi cally those w ith respect to hemodynami cs. His 
hallmark is in pioneering a method of using x-ray dye and CT 
scanning to measure blood fl ow. This intri cate research is 
making substantial contributions to several di seases including 
stroke, cancer and ca rdiac di sease. 
In stroke, clots or injury to blood vesse ls can prevent 
proper delivery of oxygen and substrates (ma inly glucose) to 
the brain. The standard treatment is thrombolysis. However, 
thi s must be done in a narrow time frame to meet current 
treatment criteri a. Dr. Lee is developing too ls to improve the 
time li mitat ion cri teria fo r treatment . He has developed 
Figure I - Pat ient # I (A) admiss ion non-contrast CT image, (B) cerebral 
blood fl ow map (sca le 0- 150 ml/mi n/ 1 OOg), (C) cerebral blood vo lume map 
(sca le 0-8 ml/ 1 OOg) obta ined 7 hours after stroke onset. ini tia l CT 
hypodensity corresponds to area of reduced CBF and CBV (solid arrow) 
whil e the dashed area shows an area of decreased CBF with normal/e levated 
CBV. Without recana lizati on, entire ischemic area at admiss ion (CBF = 
16.48, CBV = 1. 8 1) progressed to infa rcti on on the day 5 non-contrast CT 
(D). Subtle stripes of isodensity surrounded by the low density of in farcti on 
are typical fo r petechiae in cortex. Patient #2 (E) Admiss ion non-contrast 
CT image, (F) cerebral blood fl ow map (sca le 0-1 50 ml/mi n/ 1 OOg), (G) 
cerebral blood vo lume map (sca le 0-8 ml/ 1 OOg) obtained 157 minutes after 
stroke onset. Large ischemic area on th e admission C BF (dashed arrows) w ith 
an area of severely reduced CBV in the deep grey matter (so lid arrow). 
Spontaneous recanalization occurred prior to the 24 hour fo llow-up CTA. 
(H) 5-day NCCT confinns infarct in the deep grey matter (matched decrease 
in CBF and CBV at admiss ion) with progression of some surrounding ti ssue 
to in fa rcti on. A large porti on of the mismatch area at admiss ion (decreased 
CBF, nonnal/e levated CBV) recovered and did not show in farction on the 5-
day non-contra t CT. lsodense region central within the low density 
infa rcti on is typical for a hemorrhagic region. 
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Figure 2. Pati ent #3. (A) Cerebral blood fl ow (CBF ) map hows 
evere decrea e in blood fl ow in left MCA territory. (B) Cerebral 
blood vo lume (CBV) map hows similar severe decrease in blood 
vo lume a blood fl ow in the same left MCA territory. The concurrent 
decrea e in CBF and CBV sugge t that the tissue in the left MCA 
territory was already infracted with di rupted blood-brain barrier 
(BBB) as shown by the increase in BBB pern1eability in (C). This 
pati ent went on to develop hemorrhage in the left MCA territory as 
hown by the ' light haze' in the region in the non-contrast CT scan 
(D) acquired 5 day later 
In many type of cancer, hypoxic tumours are resi tant to 
treatment. Furthermore, they may undergo genetic alterati on 
re ulting in increa ed res istance to treatment, rapid proliferati on and 
advancement to metastasis. Dr. Lee' resea rch undertaking i to 
des ign a new methodology of imaging tumour hypoxia using P T/ 
CT cans as an alternative to biop y or urgery. If successfull y 
validated, Dr. Lee's research can Iran late to ph ysicians specifica ll y 
targeting hypox ic area witll higher do e of radiation and/or u ing 
drugs to enhance the effect of radiati on in order to achieve a cure. 
Si milarl y, T can of hypox ic tumour can help phy ician monitor 
effecti veness of treatment. Also, hypox ic imaging of tumours can be 
used to define selecti on criteria for pati ents that may benefit from 
genetic therapy. 
While Dr. Lee deli ver superi or results at the laboratory leve l, 
he does admit to facing chall enges in translating research from the 
bench to the pati ent bedside. There i always the confli ct between 
what is best for research and what is practi cal in a clinica l 
environment. A good example is how to use CT scanners in the 
hospital optimall y for research. He has to des ign imaging protocols 
that will acquire the necessary data but more importantly are 
acceptable to pati ents and does not slow down the workflow of a 
bu y T scanner. After all , T scanners are the workhor es of 
modern imaging department ; the demand for their use is far greater 
than the time ava il able. 
There is no doubt that the functi onal CT imaging software has 
had an internati onal impact. Since GE Hea lthca re has li censed it, it 
has been di tributed all over the world . At Dr. Lee's last count, clo e 
to 7000 copies are currently in use, ~ot onl y in orth ~merica: but 
I · A ia Europe and Australi a. He also has mternat10nal a o m s , · 0 f collaborations as a resul t of hi experti se i_n CT perfuston . ne o 
these is with the Ameri can College of RadiOlogy lmagmg Network 
(AC RIN), an organization funded by the National Can~er Institute 
(US). One of hi main research commitments was pushmg through 
an application of imaging biomarkers m cancer manageme~t, lookm_g 
at treatment efficacy, treatment response, and earl y detectiOn. H~ ts 
now in vo lved with a trial u ing CT perfusion to look ~t ovana_n 
cancer, which will hopefully be approved as the_ first maJor multi-
centre tri al of its kind with over 20 ites in the Umted States. Dr. Lee 
al 0 con tantly ha in fo rrnal co ll aborations ?ccurring, fr~m working 
with Ita lian re earchers on analysi of thetr stroke pattent data to 
getti ng hi oftware into hospi tals in China, thou~h he co~ fesse ,~hat 
that i go ing slowly. "Having the right contacts ts very dtfficult, he 
admits. " It seems a though it's till not onl y what you know, but al so 
whom you know." 
Finally and particularly, the golden question: h o:V . does he 
manage to do it all? Dr. Lee didn 't try to sugar coat tt: tt ts always 
very tressfu l, and everyone who wants to do well in hi s or her 
profes ion \ ill have this kind of tress. In the past, ht s strategy wa 
to th ink: "If onl y I could get through thi one cri i , I will be happy." 
Unfortunately, he would have one crisis after another, and thi s 
became a problem. Recently he ha come to the rea lization that 
"Happiness i a journey, not a destination." This statement, which he 
now ha taped to the wa ll in fro nt of hi s de k, wa a wakeup ca ll for 
him . He reali zed that he could not constantly li ve fro m one crisis 
moment to the next. "You can' t rea lly do thi s for long without 
burning out. You have to enjoy each step of the journey while you ' re 
trying to get to your de tination. Fortunately, being a scienti st or a 
clinician, you can have thi luxury." He now approache each day not 
onl y a a new problem, but a new learning experience, never hav ing 
to repeat what he had to do before. He reli hes hi s "Aha!" moments -
tho e that he can refl ect on to remind him ofl earning omething new. 
Havi ng th i mind et allow him to enjoy hi s journey every tep of the 
way, not just at the end. 
ltimately, what doe he want in the end? " I just want to 
tran late what i going on with my pencil and paper and animal 
re earch. It ' nice if ometh ing comes out of all the pipe dreams you 
have, ifyour methodol gy i adopted the world o er. If you can ee 
that the impact of \ hat you' re doing means omething in a clinical 
en e." Dr. Lee chuckled a he bared that ometime he finds he' 
not even acknO\ !edged in paper when hi s software i being used. 
"But I can't complai n becau e the product ha been commercialized 
and th i j u t mean people are u ing it. When what you ha e toiled 
for bea r fruit , if it is a tuall y helping patient , it make it ea ier to 
enjoy the journey." Dr. Lee al o has the quotation "Genius i only [a 
great capaci ty fo r] great patience" by Georges-Loui Leclere Buffon 
di played on hi de k. He ex plained that he was "a plodder, a late 
deve loper." ccording to him, he wa never someone who wa a tar 
upon graduating from hi PhD program. Jokingly, he uggests that 
thi BurTon quotati on is something to remember in keeping yourse lf 
out f depre ion. But it i al o important to keep in mind: 
per everance rea ll y matters. That is something to keep in mind a we 
stri ve to achieve happines during our own journeys. 
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Molecular genetics in clinical practice for the 
rapid identification of pathogenic organisms 
Roman Shapiro (M eds 2014) 
Facu lty Reviewer: Dr. Carol ine Hamm (Department of Oncology, Divisi on of M edical Oncology) 
A 50 year o ld male pre ents to the c linic w ith a hi story o f feve r and cough lasting a week. He has recently immigrated to Canada, and cannot communicate we ll . Upon examinati on, 
he is found to be hypotens ive w ith an e levated heart rate. A chest x-
ray is ordered, and it indicates pu lmonary infiltrates. This findin g, 
along with the clin ical presentati on, suggests that the pati ent has 
communi ty-acquired pneumonia. He needs treatment, but what is the 
infection that brought about thi s epi sode? What should the clini cian 
do when there is a limited amount of time to find the pathogen? 
It is establi shed that timely admini strati on of antimicrobia l 
therapy i criti ca l for good pati ent outcome. l.2·3 Unl ess the c lini ca l 
features and hi story are very suggesti ve of a particul ar causati ve 
agent, the therapy must be empiric. The recommendations in thi s 
case are to begin with broad-spectmm antibioti c therapy, and to 
adjust the treatment regimen once laboratory cultures identify the 
best antibiotics to use .2 This approach, a lthough logical g iven the 
current potent ial of identi fy ing the causati ve agent, is fraught wi th 
problems. For one, inappropriate initi a l empi ric therapy is an 
independent ri sk factor for increased patient morta li ty and durati on 
of hospitalization.4 Furthermore, the use o f a vari ety of antibioti cs 
may promote the deve lopment of antibioti c resistance among 
pathogenic organi sms. Idea ll y, once the c lini ca l picture is suggesti ve 
of an infectious cri sis, rapid identificati on o f the causati ve agent 
would a llow for targeted therapy that optimizes outcome while 
minimizing the ri sk for the deve lopment of antibioti c resistance.2 
While current medi ca l techno logy does not have th e rapid 
identification capacity in a ll cases of infecti ons, it is progress ing 
steadily towards thi s goa l with the applicati on o f molecular geneti cs 
in the clinica l environment. 
GENOTYPlNG 
The di stinguishing characteri sti c of every organism must li e in 
its genes. Two pathogenic bacteri al o rga ni sms may appea r a like in 
presenting clinica l symptoms, on gram sta in , and in the ir growth 
characteri stics, yet be di stinctly di ffe rent and require di ffe rent 
treatment. The differences between these organi sms that cannot be 
seen based on culturing and stai ning a lone w ill be re fl ected in the ir 
geneti c make-up. Gene sequencing, there fore, is an excell ent 
approach for the identifi cati on of a parti cular infectious orga ni sm 
from a slew of poss ibi liti es .5 As sequencing techno logy becomes 
more e ffi cient, the approach will not onl y be hi ghl y sensiti ve and 
specifi c, it w ill be rapid and inexpensive. Before thi s can happen, 
however, hurdles must be overcome. One i specific ity - there must 
be an identi fy ing geneti c sequence for every pathogenic o rgani sm. 
This is no easy task g iven the large vari ety of known pathogeni c 
species as we ll as newly evo lving ones . But the automation of gene 
sequencing coupled with computer process ing power a llows for the 
a lignment of who le genomes from di ffe rent pathogeni c spec ies in 
order to identi fy key differences that can be u ed to di stingui h one 
in fection from another.6 As these geneti c d iffe rences are identi fied, it 
remains for highl y sensiti ve tools to be developed that can assay fo r 
the di ffe rences in clini ca l specimens. 
Let us return to the pati ent w ith pneumonia symptoms. He i 
recentl y immigrated, meaning the infec ti on could have been picked 
up at hi s place of ori g in . One of the most common globa l human 
in fec ti ons is w ith members of the fa mily Mycobacteriaceae.7•8 They 
can be missed as causes of communi ty-acquired pneumoni a because 
of the absence of readi ly ava ilable rapid di agnosti c tests.9 Recent 
technologica l advances have made progress in recti fy ing thi s 
problem. In identi fy ing a mycobacteri a l causati ve agent, it would be 
important to di stingui sh tubercul ous mycobacteri a from non-
tu berculous mycobacteri a (NTM)8 ·1° Furthermore, it would be 
important to determine the parti cular subspec ies as this can be critical 
in identi fy ing the source of the infecti on8 Taking advantage of 
known genomic data for the mycobacteri al organi sms, multipl ex 
PC R is one assay that can be used. 
MULTIPLEX PCR 
The princ iple of the polymerase chain reaction (PC R) is to 
specifica ll y amp li fy a target DNA sequence using thennostable 
enzymes such as Taq polymerase or Pfu . 11 The sequence to be 
amplifi ed is loca lized between two DNA primers that hybridi ze to the 
target DNA. The maj or advantage of thi s technique in clinical 
di agnosi is that it requires very littl e starting mate ri a l for 
amplifi cati on.12 For in fec tions w ith mycobacteri a, thi s could allow 
for identifi cati on without the culturing step that i so time-
consuming.13 Unlike traditi onal PC R techniques whereby a single 
target sequence is amplifi ed, mu ltiplex PCR is able to specifica lly 
ampli fy severa l target sequences in one reacti on.8·14 Thi s poses 
severa l technica l cha llenges because every sequence in the reaction 
requires an optimal temperature and buffer for amplificationi 4 
Furthermore, once the reaction conditi ons are optimized it is 
necessa ry to di stingui sh one amplified sequence from another. When 
these cha llenges are overcome, it is possible to ampli fy severa l 
species-specific geneti c sequences, including testing fo r the presence 
of antibioti c-res i tance genes. 15.16,17 
In the case o f mycobacteria l infections, mul tiplex PCR can 
di tingui sh between M tuberculosis complex (MTC) and NTM based 
on known genetic differences.1 ·19 These have been tested on clinical 
spec imens, yie lding hi gh sensiti vity and specifi c ity.B. I9.l0,21 Other 
multiplex PC R assays ex ist that can di stingui sh between the TM 
ub pec ie , in particul ar those of the Mycobacterium avium complex . 
8 The major adva ntage of a ll of these assays is the sensiti vity and 
rapidity of PC R, a ll owing for very small amounts of DNA sequences 
to be detected w ithin severa l hours.12 However, results must be 
interpreted w ith caution, as the poss ibility of fa lse negatives is 
con ide rable when runn ing severa l PC R amplifi cati on reactions at 
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once 14 In addition PCR may be prone to fa lse positi ve results since 
very .minute amou~ts of DNA may be amplified considerabl y. 12· 14•21 
SPOLIGOTYPING 
Whereas multiplex PCR has found a use in di stinguishing. MTC from 
NTM and identifying subspecies of the NTM group, spoli gotypmg IS 
a method that has been developed and used to identi fy and genotype 
strains of bacteri a in the MTC group22•23 The method is ba ed on the 
presence of conserved direct repeat (DR) sequences separated by 
non-repeating spacer regions in the genomes of these bactena. 
Di fferent strain vary in the number of such DRs as well as the 
length and sequence of the space r regions22 By des igning 
oligonucleotide primers that hybridize to conserved regions within 
the DRs, it is poss ible to run a PCR reacti on that yield a large 
variety of amplified D A sequence of different sizes (Figure I A) . 
The pattern of the e amplified D sequences is characteristi c of a 
strain of MTC bacterium (Figure I B)22 
A 
... .. 
restnct1on fragment length polymorphism (RFLP) a?alysis.26 The 
latter method is based on the digestion of mycobatenal DNA With 
endonucleases, and the reso lution of species-specific fragments by 
com pari on of their migrati on patterns on a geJ.28 
rtPCR is a technique that allows for the rapid, quantitative 
amplificati on of DNA using PCR. As the P.CR reaction is run, the 
PCR product generated during each cycle IS bound by a dye that 
fluoresces at a particular wave length when ~ound to double-stranded 
DNA. The resulting fluorescence is quantified dunng each cycle, 
yielding a rea l-time DNA amplification. curve .12 The amplification 
product is then subjecte? to HRM analys is, whereby a .known am~~~! 
of D A i melted by ra1 mg the temperature m fi xed mcreme~ts . · 
Since the melting temperature (Tm) of double-stranded D A IS very 
ensiti ve to equence29, a ignifi cant difference in Tm may be 
ob erved between Beiji ng and non-Beijing trains of Mycobacterium 
by virtue of a ingle P. 
rt PCR wi th HRM analy i wa appl ied to clinical specimens and 
B 
Figure 1. The bas ic principles invo lved in spoli gotyping. A Two juxtaposed blue rectangle indicate a conserved direct repeat (DR) in the 
genome of a parti cul ar strain of Mycobacterium tuberculosis complex . Onl y a ubset of DRs are shown for clarity, whereas there would be many 
more in the actual organi m. PCR primers are des igned to hybridize at particular locations within the DR a shown by the arrows. An arrow 
pointing to the ri ght i a forward primer, while one pointing to the left i a rever e primer. The primers may hybridi ze at any of the DRs, and the 
resulting pos ible PCR products are indicated. The red square indicates a specific equence in the fir t pacer region, while the yellow rectangle 
indicate a pecifi c equence in the econd space r region. B The PCR products fro m A are hybridized to an array containing immobilized 
oli gonucleotides whose sequences CO ITespond to a spacer region. Examples of thi arc demon trated with the red square and yellow rectangle 
from A, whereby the equence in each of the co loured rectangle is recogni zed by a spe ific oligonucleotide probe on the array. Hybridizati on 
between a PCR product and the array is ind icated by a black circle on the spoligotype. Each row on the array corre pond to hybridizati on 
signals from a single train . 
poli gotyping has been applied to clinica l spec imens23•24 It is a 
rapid a ay becau e it relie on PCR, and studies have shown that it 
is sensitive and speci fi c to MTC infections.22 ·23 It has the additional 
advantage of bei ng able to di tingui h trains of M. bovis from those 
of M. tuberculosis, a di ffi cult task with traditional techniques22 
Much of the u e of poligotyping has in vo lved contact tracing in 
instances of u pected MTC infecti ons so a to limit the spread of 
infec ti on.22•25 Fu rther studi es are undergo ing to definiti ve ly 
determine its use in clinica l di agnos is and genotyping of MTC 
infecti ons. 
REAL-TIME PCR (rtPCR) WITH HIGH-RESOLUTION 
MELTING ANALYSIS (HRM) 
A spoligotype performed on clinica l isolates from the pneumonia 
pati ent revealed a pallern consistent with a hi ghly virulent spec ies of 
Mycobacterium belonging to the Beijing lineage.26 This lineage is 
known to be highl y tran miss ible and often drug-res i tant, requiring 
spec ifi c treatment reg imens that differ from other mycobacteri al 
infecti ons27 For the purpo es of rapidly confinning an infecti on with 
thi s pathogen, one a say that can be used is rtPCR with HRM 
analysis. Thi assay reli es on the presence of a single-nucleotide 
polymorphi m ( NP) corresponding pec ifi ca ll y to the Beijing 
lineage that was identi li ed u ing methods such as spoli gotyping and 
re ulted in nearly 100°o ensiti vi ty and spec ificity as long a there 
was a uffi cient load of bacterial orga ni sm in the sputum .26 It ha the 
additional ad antage of being very rapid and relati ve ly inexpensive 
to perform .29 When clin ica l iso lates from the patient with pneumonia 
ymptoms were subjected to the a ay, the pre ence of the Beijing 
lineage of M. tuberculosi was confirmed. 
CONCLU ION 
The assays mentioned here in the context of a poss ible infecti on with 
a member of the family Mycobacteriaceae are intended to 
demon trate the utility of the gene sequence in rapid clinical 
di agno i . Improvements in the effi ciency of gene sequencing a well 
as bioinformatics analys i are generating a large amount of data 
regarding peci fi e geneti c target for each pathogenic organism that 
could be as ayed by techn iques based on PCR. Some of these 
technique , including multip lex PCR, spoligotyping, and rtPCR with 
H RM demonstrate that assays can be des igned and implemented in a 
clinica l setting to identi fy parti cular infectious organisms. A the e 
as ays become less expensive and standard in all microbiological 
laboratori e , their rapidity will all ow for the u e of appropriate 
targeted therapy in order to optimize patient health whi le minimizing 
the nsk of the development o f antibi otic res i tance. 
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The application of three dimensional laser 
surface scanning and imaging in a case of total 
nasal reconstruction 
Michal Brichacek (Meds 2013) 
Faculty Reviewer: Dr. Douglas C. Ross, MD MEd FRCSC (Department of Plastic Surgery) 
T he earliest reports of reconstructi ve surgery are presented in an ancient Egyptian medi ca l text dating back to 1600 B.C. that describes the treatment of nose, ear, lip, and chin injuri es .1 
However, it was Indian surgeons who are credited with empl oyi ng 
the first de finiti ve plastic surgery techniques, with spec ifi c report 
describing Sushruta performing the fir t rhinoplasty in 500 B.C.2 
Pl asti c surgery developed at a time when there was a 
tremendous need for reconstructi ve correction o f catastrophic 
deformities : after World War 1_3 Never before had surgeons been 
presented with such extensive injuri es that required complex and 
innovati ve reconstructi ve procedure . The Greek work plastikos, 
meaning to be capable of bei ng molded, wou ld become used to 
describe a fi eld where surgeons molded tho e devastated by the 
injurie of war4 
As technologica l advance have improved protecti ve gear and 
medi cal advances have improved advanced trauma care, the 
proportion of soldi ers dying in combat a a result of thei r injuri es has 
markedly decreased. Soldiers are currentl y survi ving injuries that 
would have kill ed them in any prev ious conflict, but as a result they 
are survi ving with massive facia l and crani a l injuri es that require 
complex reconstruction. 
PATIENT PRESENTATION 
M.F. is a 2 1-year-old African American wa r veteran who sustained 
signifi cant facia l and body trauma in Iraq. He was 
in vo lved in a situation where a vehi cle ex ploded and 
he ultimate ly rece ived multipl e oft ti sue injuries 
and facia l fractures . This resulted in amputati on of 
hi s left arm and left him with an ex tremely fl a ttened 
nose. He presented to Johns Hopkins Ho pita! 
seek ing nasal reconstruction. 
Nasa l recons tru cti on wo uld have to be 
performed through a midline forehead flap, where a 
large fl ap o f skin is taken from th e middle of th e 
forehead, rotated, and fold ed dow n to create a new 
nose.5 Due to the lack of underl y ing ca rtilage to 
prov ide support for the nose, rib ca rtil age would 
have to be harvested and a nasa l subsurface would 
have to be recreated. Additiona lly, a radi al forearm 
free ti ssue transfer would need to be performed to 
provide a vasculari zed interna l skin lining for the 
di sta l half of the nose. 
flap would still be intact, whi ch means there was a significant chance 
of it fai ling and becoming necroti c. 
Despite these risk , the patient fe lt very strong ly opposed to a 
nasa l prosthesis and expresses hi desire for surg ica l reconstruction . 
Bei ng aware of the igni ficant ri k of com plications and the need for 
multiple stage , the patient elected to proceed with urg ica l 
reconstruction. 
TECHNOLOCICALPLA I C 
The no e is a complex three-dimen ional object that must be in 
harmony wi th the remainder of the face . The cha ll enge with thi s case 
was to create a new nose from nothing. In extensive facial soft tissue 
injures the surgeon can use the remnants of the nose as a guide in 
order to create a new nose. In thi s case, even the cartil age, which 
serves as a framework fo r the no e and could act a a guide, was 
absent. 
It was decided that technology could he lp with thi problem by 
providing the surgeon with two types of guides to a id him in the 
reconstructi on: a two-dimen iona l template showing the complex 
area of kin that must be taken a a fl ap from the forehead, and a 
three-dimensional plastic mold bowing the fin a l shape that the 
surgeon should tri ve to achi eve during the creation o f the ubsurface 
framework of the nose. 
The Art as App li ed to Medicine 
di vision at Johns Hopkins began by taking a 
plaster mold of the ex isting condition of the 
patient' face. U ing thi s and photographs 
prov ided by the patient 's fa mily, a wax 
model wa created of the patient ' nose 
be fore hi s injury. This wax mode l wa then 
ca t in pi a ter and sent to Direct Dimen ions 
Inc. (Owings Mill s, Maryland) for surface 
scanning and digital manipu lation of the 
re ulting 3-dimensiona l mode l. 
The mold is scanned usi ng a laser 
However, the patient was informed that he was 
not a good candidate for thi s procedure due to the 
need for multip le stages and hi s elevated ri sk for 
failure . Due to hi s signifi ca nt fac ial oft ti ssue 
injuri es, it is unlikely that the blood suppl y to thi s 
Figure I. Three-dimensional laser 
scanning is used to create a di g ital 
model of th e pati ent 's face in the 
orig ina l conditi on. 
urface scanner (Perceptron Laser Scanning 
Sy tems, P lymouth, Michigan) that creates a 
three-dimensional point c loud of data that i 
converted into a resulting three-dimen ional 
computer model using PolyWorks oftware 
(lnovmetric Software Inc, Quebec City, 
Quebec, anada). In the same manner, the 
patient ' injured face was then Ia er smface 
canned and created into a three-dimens iona l 
computer model (Figure 1). 
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Figure 2. A three-di mensional translucent 
plastic mode l served as a guide for the nasa l 
tructure during the procedure, while the 
two-dimensional shaped served as a gu ide fo r 
harvesting of the fl ap fro m the fo rehead. 
More recent ly, the implementation of three-
dimensional object canning and vi sualization ha 
been applied in the medical field to provide great 
benefit to both surgeons and patients a like. By 
app lying this technology, a radiation shi e ld was 
created to protect adjacent tissues in the treatment 
of head and neck cancers.6 The creation of three-
dimensiona l breast mode ls through imaging has 
become possib le in order to help guide surgica l 
manageme n t 7 In more of a mai nst rea m 
applicati on, surgeon can show patients expected 
res ul ts after surge ry in a dy nami c th ree-
dimensiona l view usi ng imaging systems such as 
the Canfie ld Vectra M3 (Canfie ld Scientific Inc, 
Fa irfie ld, ew Jer ey) or the Ax is T hree XS200 
(Ax is Three Inc, Boston, Massachusetts) . 
The pat ient in thi s case presented with an 
extremely cha ll eng ing defect due to a combinati on 
of signi fica nt facia l soft tissue trauma, multi ple 
facia l fractures, as well as the absence any 
fra mework. Ca es of total or subtota l nasa l The three-dimensiona l model of the pre-mj ury nose wa then 
superimpo ed into the proper pos ition on the patient 's inj ured face, 
show ing a three-dime ns io na l re nditi o n of what th e idea l 
reconstruction would achi eve. From thi s combined model engineers 
were able to determine the dimensions of a three-dimensional model 
molded in clear plastic to be used as a surg ica l guide, and usi ng 
complex mathematica l simulations engi neers were able to unroll the 
complex shape of the three-dimensional pre- inj ury nose onto a fla t 
two-dimensional surface. (Figure 2) Th is served as a guide to the 
surgeon during the procedure for both the shape and size of the fl ap 
of tissue to be harvested from the forehead. 
Ultimately, the pat ient req uired six separate procedures to 
complete hi s reconstruction. His recovery was complicated by an 
MRSA infec tion as well as a sma ll degree of dista l fl ap necrosis. 
Fortunately, total fl ap necrosis did not occur and the remainder of the 
flap was salvaged. The patient was extremely pleased with the result 
and was extremely satisfied that he was able to have both the fo m1 
and function of hi s nose restored (F igure 3). 
Figure 3: The pati ent shown from a side-view preoperative ly (a) and 
postoperati vely (b). 
ubsurface nasa l 
reconstructi on are part icu larly cha llengingly as the reconstructed 
structure must be vascular in order to hea l predictably, stable in order 
to withstand the scar contracture and maintain symmetry, yet at the 
ame time be fu nctional enough to be acceptab le to the pati ent 's 
li festy le.8 
The construction of an abstract th ree-d imensional obj ect such a 
the nose from a fl at segment of ti ss ue is extremely di ffic ult in the 
absence of a subsurface fra mework. By using novel technological 
innovations invo lving three-dimensional laser surface scanning and 
imaging, the li kelihood of achi eving a favo rable resul t is potenti ally 
increased. The creati on of a custom made translucent template fo r 
use during the procedure is achieved by the combined efforts of the 
pat ient, the anaplasto logist, and the surgeon.8 The template is created 
such that it anti cipates the thi ckness of the skin that will be provided 
by the fo rehead fl ap and serves as a surgica l guide for the surgeon in 
the c reation of the subsurface framework of the nose. 
The applicati on of three-dimensional laser surface scatming and 
modeling is a powerful tool that can be utili zed in order to aid in the 
visuali zati on of cha ll eng ing defect as help in the surgica l 
reconstructi on of the e defects. A lthough still in its in fancy, as thi s 
technology evo lves and its fu ll potentia l becomes rea li zed, it w ill 
ure ly fi nd many more appl ications in medic ine and particul arly in 
the fie ld of reconstructive plasti c surgery. 
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F or many people, the words "min imall y in vas ive surgery" conjure up vision of medica l robots, MRJ machines and nanotechnology. Although we frequentl y herald minimall y 
invasive procedures as the fu ture of surgery, the concept is much 
older than most of the technology it is associated with . It is an 
ancient vision enabl ed by many technologica l deve lopments 
unrelated to medicine - the introduction of electric ity, digital video, 
video game graphics, and industri al robots have all played major 
roles in shaping the way surgery is practi ce today. 
WORKlNG IN THE DARK 
The first documented attempt to "look inside" the internal organs was 
described by Hippocrates (460-375 BCE) in a pa sage referring to a 
rectal speculum (Figure I ). 1 Roman medicine also describes similar 
instruments, including a three-bladed vaginal peculum from the 
ruin of Pompeii .3 The initial attempts to make a di agnos is by 
examin ing internal body orifi ces all faced the same problem: 
inadequate lighting. Almost all of the early too l were designed to 
max imize the amount of external ambient li ght avail able for direct 
visuali zati on of internal structures. 
Figure 1. xample of a rectal speculum similar to the one described 
by Hippocrates. Image courtesy of the Historica l Co llecti ons & 
Services of the Hea lth Science Li brary, Uni versity of Virginia. 
The first attempt to design a tool pecifica ll y guiding li ght to the 
target was an instrument call ed the " Lichtl eiter" des igned in 1806 by 
Phillip Bozzini ( 1773-1 809), a young obstetrician (Figure 2) . This 
device was an elongated thin funnel that could be passed into an 
orifi ce. The end of thi s dev ice wa a stand carrying a candle for 
lighting. Refl ectors directed candlelight down the funnel. Many 
funnel of different sizes could be u ed, and it could help examine 
the bladder, rectum, vagina and nasopharynx. Although Bozzini is 
now. credited with creating the first endoscope, the device was poorly 
received. The candle produced heat and smoke leading to burns, the 
device could be painful to introduce, and lighting was stil l 
inadequate.2•3 In the foll owing years, attempts were made to improve 
the des ign by many people including Pierre ega las (1 792 - 1874), 
John D. Fisher (1798 - 1850), and Antonin J. Desormeaux (18 15 -
1894). Desorn1eaux was the fi r t to use an endoscopic instrument for 
therapeuti c purposes when he used his endo cope to remove a 
papilloma from the urethra.4 Eventuall y, it was reali zed that "to light 
up a room one mu t carry the lamp inside2, and the idea of the 
endoscope it elf as a I ight source was born . 
Figure 2. Construction drawing of the " Bozzinischer Lichtleiter". 
Image courte y of the Medica l Univer ity of Vienna, Department of 
Hi tory of Medicine . 
. With the invention of the incande cent light bulb by Thomas 
d1 son ( 1847- 1.9.3 1 ), endoscopy began to be taken more eriously by 
med1 ca l practitioner . There were imultaneous developments 
~ystoscopy, thoracoscopy, and gastroscopy. Many modification and 
~mprovements were made to endo cope des igns in the 20'h century, 
1ncludmg the u e .of insuffl ati on by Georg Kelling, and the 
development of fl ex ible fibre-optic in truments pioneered by Bas il 
Hirschowitz ( 1925)5 ' 
FROM OLAGNO IS TO TREATMENT 
While therapeuti c applicati on of laparoscopy began in the 1930 , the 
deve lop~1ent of the computer chip television camera was a key piece 
of ena b1J~1g tech.nology for. the u ~ of endoscopy to guide surgery and 
therapy 111 addition to di agnostic uses. Video-endo copy allowed 
endoscopic surgeons t~ tand upright and u e both hands to carry out 
the proce~ure. In addition , the entire operating team was able to view 
th e magnifi ed 1mage on a monitor. In the 1980s, CCD cameras 
became small enough that it became po sible to integrate them into 
too ls. In conjuncti on with these changes was the development of 
spec ialJ.zed tools for ~~doscop1c procedures. The e typically had a 
form . s m~llar to traditional too l , but with a long straight shaft 
all owmg Ill erllon Into the body cavity. 
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SEEING "WITHIN" 
While endoscopes allowed surgeons to see inside body cavi ti es, their 
vision was till limited to the outer surface of organs. Frequent ly 
tumour and other abnonnal ti ssues were buried under a layer of 
normal tissue. Physicians had to "hunt" around for their targets, 
usually in a trial-and-error process that could result in the remova l of 
large sections of normal ti ssue. The discovery of X-ray in 1895 by 
Wi lliam Rontgen allowed physicians to ee in ide ti ssues for the first 
time. X-rays were immediately used for diagnosti c purposes, 
including the planning of surgical interventions: 8 day after the 
publication of Roentgen' first paper, J. H . Clayton a surgeon in 
England used an x-ray print to remove an industrial ewing needle 
from a woman's hand.6 However, an actual x-ray guided intervention 
did not occur until 1963, nearly 70 year later when Charl es Dotter 
percutaneously dilated a tight tenosis of the superfi cial femora l 
artery7 Today, fluoroscopy-guided interventions seem intuiti ve and a 
natural app lication of x-ray images. However, early images could 
take up to two hours to produce, and continuous imag ing was not 
possible.8 
An explosion of new techniques and procedures followed the 
key deve lopment of video-endoscopy and inte rventional 
fluoroscopy as these technologies were applied to a range of different 
problems. While these modalities conti nue f01m the mainstay of 
image-guidance for minimally invasi ve procedures, recent years have 
seen the exploration of many other modalities for the guidance of 
intra-operative procedure . Some example include: 
intra-operati ve MRJ for brain tumour remova l9, epilepsy 
surgery 10, ca th eter-based aortic va lve pl acement 11 , 
catheterizations 12, and stenting of aorti c co-arctation l 3 
intra-operati ve CT for brain les ion and sinu surgery 14 
ultrasound-guided breast surgery15 
Cost, acquisition speed and diffi cul ty in making the imaging sy tems 
OR compatible remain barriers to intra-operative CT and MRI 
guidance of surgical procedures. As real-time imaging has grown in 
populari ty, it ha become increasingly important to develop new 
surgical tools that do not introduce artifacts into the images. This 
requires changes in both the mechanical design and the materia ls 
used. 
ROADM APS 
There were also early attempts at minimall y invasive surgery wi thout 
the use of any real-time imaging to locate internal structure . In lieu 
of direct visualizati on, a model was used to help the physician 
Figure 3. Horsely - Clark stereotactic frame. I mage courtesy of the 
Sc1ence Museum, London, UK. 
( 
estimate the location of internal structures. A paper published by 
Hor ley and lark ( 1908) described a stereotactic device that cou ld 
be affi xed to a subject's head and aligned using ex ternal landmark 
such as the auditory . canals and orbital rim (Figure 3 ).16 This 
al1 gnment dev1ce prov1ded a coordinate system that could be used to 
guide the introduction of electrodes into the kull. This was the first 
time an attempt was made to correlate a model of the internal 
anatomy with the patient in phys ical pace. Horsley and Clark 
as um~d that brains pos essed a con tant tructure and that every 
bram IS the same as another, and that spec ific internal structures 
~ould be targeted by simple coordinates. Although this assumption is 
mcorrect, the des ign of the stereotactic frame was a major 
br.eakthro~gh that would later allow pre-operati ve images to be 
aligned w1th the patient for procedure guidance (The invention of 
stereotacti c frames actually preceded the invention of CT and MRJ 1 ). 
~he abi li ty to bring models and image into the patient's 
coordmate sy tem was an important step in allowing models to be 
used for planning and guidance of procedures. With the in vention of 
CT scanners in 1973 (Hounsfield , 1919 - 2004), CT stereotactic 
surgery became possible. The use of pre-operat ive images to guide 
mtervent10ns IS a current area of research of research and growth 
(F1gure 4). xamples of clinically used sy tem include the Carto 
XP EP Navigat ion System ( me rges CT o r MRI with 
electroanatomica l information for catheter ab lations) and the 
Medtronic Stealth Station (merges pre-operat ive CT and MRJ images 
w1th tracked surg1cal tools and intra-operati ve images) .11.18 
Figure 4. Example of multimodality imaging showi ng overl ay of 
CT and U image of the aortic root. 
MOTION AT A DI STANCE 
With minimall y invas ive access to internal structures through small 
ports, tools became more diffi cult to control and navigate. In 
respon e to these challenges surgical robots were developed. Adapted 
from industri al des igns, the first medical robots were designed to 
hold a fixture at a specific location in space. 19 The first robot used in 
surgery was an indu tri al robot called the PUMA 560 that held a 
fixture next to a patient's head to locate a biopsy tool in neurosurgery 
(Figure 5).20 However, shortl y after thi s initial breakthrough, the 
company that manufactured the PUMA 560, Unimation Limited, was 
sold to Westinghouse Limited, which refused to allow the robot to be 
used for surgical purposes on the bas is that it was un afe.21 Soon 
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Figure 5. Photo of the PUMA 560. Image courtesy o f Unmann ed 
So lutions Inc. 
companies began deve loping robotic systems specifica ll y fo r medi ca l 
appli cati ons. The first to be tri ed on human pati ents was developed at 
l.BM and ca ll ed the Robodoc. It was used to hold a rotating cutter 
that reamed out the prox imal fe mur to take a prosthetic implant. 22 
Today, medi ca l robots are used routinely for many procedures, 
inc luding coronary artery bypass gra ftin g and transpubic radi ca l 
prostatectomy. 
Surg ical robots can provide many advantages, inc luding the 
abi lity to move in predefin ed 3D paths, the abi lity to hold too ls fo r 
long periods of time ri gid ly and without tremor, the abi lity to make 
precise mi cromoti on and the abili ty for te le-operati on. However, 
surg ical robots can also be bu lky, expensive, and diffi cult to nav igate. 
Today it is sti ll unc lear whether surg ica l robots prov ide c lini ca l 
adva ntages over computer a ided surgery, in whi ch nav iga ti on and 
placement o f surgica l tools are a ided by images and measurements 
provided on a computer, but the too ls remain manuall y contro ll ed by 
the surgeon. 
LOOKrNG FORWARD 
Since th e 1980s there has been an ex plo ive interest in minim all y 
mvas tve procedures and the techno logy behind it. As ph y ic ian 
become more comfortable and co nfident w ith the new techno logy, 
they a re attempt!ng increas ingly complex procedures minim all y 
mvastve ly - spurnng on the eng ineering o f new dev ices and yste ms. 
Meanwhil e, the study o f interac ti ons be tween surgeons and these 
too ls has deve loped into a resea rch area o f its own. Wh at d es th e 
futu re hold? Mul timodality imaging platform , teerable robot , 
nanobots and augmented rea lity? 
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